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Abstract
Cardiovascular disease is one of the leading causes of death in Canada. Treatment
currently focuses on preventing the increase of sympathetic signaling seen in heart
failure. However, it has recently been noted that cardiac function is dependent on
parasympathetic tone. Previous studies have demonstrated the development of heart
failure when cholinergic targets are knocked out in cardiomyocytes. Transgenic mouse
models that have increased cholinergic transmission show protection against
cardiovascular insults. We have shown that transgenic mice overexpressing vesicular
acetylcholine transporter in cholinergic cells show cardiovascular protection in response
to ex vivo insults. As well, this protection is seen when cholinergic signaling was
increased using acetylcholinesterase inhibition. Moreover, although no differences on
cardiovascular parameters were seen in response to in vivo acetylcholinesterase inhibition
alone, it was found to re-establish hemodynamic parameters and prevent cardiac
hypertrophy and fibrosis in response to a hyper-sympathetic mouse model. In conclusion,
increasing cholinergic transmission provides protection against cardiovascular insults.
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Chapter 1
1 Introduction
Cardiovascular (CV) disease is one of the leading causes of death in Canada and
around the globe (Boisclair et al., 2018). With increases in technology, there are more
cases of CV disease being diagnosed, as more people are surviving heart related injuries,
as well as an increase in the aging population (Roth et al., 2015). Types of CV disease
include ischemic heart disease, myocardial infarction, and heart attack. As well,
hypertension and cardiac hypertrophy are underlying risk factors for the development of
heart failure (Wilson & Levy, 1999). Treatment for CV disease include a magnitude of
lifestyle changes, pharmaceutical agents, surgical procedures, and rehabilitation.
Continuing the search for therapy is imperative, as this will provide alternative targets,
useful for those who have become desensitized to common mechanisms of action, such as
the commonly used beta-blockers, ACE inhibitors and vasodilators to prevent
sympathetic overdrive (Sabbah, 2004; Barrese & Taglialatela, 2013; Jensen et al., 2014;
Sukoyan et al., 2017). Therefore, improved prevention and treatment regarding CV
diseases is necessary.

1.1 Heart Function
It is essential that the heart pumps efficiently, maintaining blood flow necessary to
provide peripheral organs and tissue with adequate nutrition. Failure to do so leads to
oxygen deficient organs, which has an infinite list of consequences. Upon activation of
the sinoatrial node, the pacemaker of the heart, a contraction occurs down the atria, to the
atrioventricular node, leading to propagation of conduction down the bundle of his

2
(Hoffman, 1967). Conduction travels up the Purkinje fibres allowing the ventricles to
contract, pumping blood out through the aortic valve and to the periphery (Hoffman,
1967). Systole refers to the state of the heart during contraction, whereas diastole refers to
relaxation. In response to stimuli, the heart can increase or decrease contractility and rate,
ionotropic or chronotropic parameters, respectively. This is controlled through actions of
the autonomic nervous system (Hoffman, 1967).

1.2 Autonomic Control of the Heart
The autonomic nervous system (ANS) is the neural connection between the brain
and various organs. More specifically, autonomic signaling is responsible for the
maintenance of cardiac homeostasis (Gordan et al., 2015). Mechanical, chemical, and
thermal stimuli influence the ANS to activate or inhibit relevant pathways or signal
cascades. The ANS has two divisions, parasympathetic and sympathetic, both of which
are crucial for proper heart function. The sympathetic division utilizes norepinephrine
(NE) as its main neurotransmitter (Hoffman, 1967). NE binds to adrenergic receptors at
the heart, found primarily on the sinoatrial (SA) and atrioventricular (AV) nodes.
Activation of these electrical pathways leads to an increase in heart rate (HR) and
contractility (Triposkiadis et al., 2009). This is mainly done through beta adrenergic
receptors, increasing chronotropic and inotropic parameters (Madamanchi, 2007). In
contrast, activated alpha adrenergic receptors, found predominantly on blood vessels
cause vasoconstriction, increasing blood pressure (Just et al., 2000). Acetylcholine (ACh)
is the neurotransmitter utilized by the parasympathetic division of the ANS to induce

3
opposite effects. ACh binds to muscarinic receptors, primarily found in SA and AV nodes
to decrease chronotropic and ionotropic parameters (Dhein et al., 2001).

1.3 Role of Sympathetic Nervous System in Heart and Associated
Receptors
Sympathetic communication at the level of the cardiomyocyte is through both
alpha- and beta-adrenergic receptors. Upon activation, these G-protein coupled receptors
(GPCRs) undergo a conformational change, leading to downstream signaling pathways,
which induce increases in chronotropic and ionotropic parameters. Although betaadrenergic receptors (β-AR) are the predominant adrenergic receptor expressed in
cardiomyocytes, there is some expression of alpha-ARs (Bristow et al., 1988).

1.3.1 Alpha Adrenergic Receptors
Although not the most abundant adrenergic receptor, alpha 1 ARs are found in
both human and rodent heart tissue (Bristow et al., 1988). Activation of these receptors
causes a downstream intracellular release of Ca2+ due to coupling of Gq/11 protein and an
increase of inositol triphosphate (IP3) (Bristow et al., 1988). Amongst the three subunits,
alpha 1 is the most abundant transcript in rodent heart; although, recent data suggest that
it is found in only some myocyte populations. Sustained treatment using alpha 1 agonist
suggest that activation causes cardiac hypertrophy but no fibrosis (Jensen et al., 2014).

1.3.2 Beta Adrenergic Receptors
β-AR are the most abundant AR in the heart; specifically, β1-AR contribute to
80% of all cardiac β-AR (Madamanchi, 2007). β2-AR are found at around 20% and β3 are
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minimally found in cardiac tissue (Madamanchi, 2007). Upon activation, β-AR couple to
Gs proteins, which ultimately leads to an increase in cyclic adenosine monophosphate
(cAMP). This signaling molecule activates protein kinase A (PKA) to increase
contractility of the heart (Madamanchi, 2007). On the other hand, β2-AR can also couple
Gi protein. The Gi alpha subunit causes a decrease in cAMP levels and activates cytosolic
phospholipase A2 (cPLA2) causing increased calcium signaling and cardiac contraction
(Madamanchi, 2007). It has been recently noted that the β2 adrenergic signaling pathway
is regulated by the abundance or coupling of β1 signaling; deficient β1 pathway promotes
the β2 pathway (Madamanchi, 2007). These receptors also undergo desensitization
through negative feedback during prolonged exposure. Desensitization of β-AR has been
suggested as a contributing factor to the development of HF (Madamanchi, 2007).

1.4 Parasympathetic Nervous System and its Role on Heart Function
The parasympathetic system, otherwise known as the cholinergic system, utilizes
ACh as its neurotransmitter to allow communication between autonomic pathways and
peripheral organs. ACh is found in both pre-ganglionic and post-ganglionic neurons
(Gordan et al., 2015). Upon activation with ACh, nicotinic receptors, found
predominantly in neuromuscular junctions, convey neuronal transmission for skeletal
muscle control (Gordan et al., 2015). However, at the level of the cardiomyocyte, ACh
binds to Muscarinic type 2 (M2) receptors to elicit a response. More specifically, M2
receptor activation at sinoatrial and atrioventricular nodes of the atria causes a decrease in
chronotropic and ionotropic responses (Dhein et al., 2001). Interestingly, neural
innervations of the vagus nerve are more dense at the atria compared to the ventricles
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(Brodde & Michel, 1999; Gordan et al., 2015). Although there are sparse innervations at
the level of the ventricle, vagal activation has only been found to decrease chronotropic
and inotropic parameters in response to previously upregulated activity (Brodde &
Michel, 1999). Upon activation of M2 receptors in whole heart tissue, the coupled Gi
protein inhibits adenylyl cyclase, decreasing intracellular levels of cAMP (Brodde &
Michel, 1999). This decrease in cAMP leads to decreases in Ca2+ current as there is less
activation of L-type Ca2+ channels, lessening force of contraction. In addition, PKA
activity is inhibited by M2 activation, also decreasing contractility. There is an increase
of potassium current that is also a result of ACh activation of M2 receptors through the
Giβγ subunit (Logothetis et al., 1987). Activation of inwardly rectifying K+ channel
results in hyperpolarization, decreasing heart rate and force of contraction ((Brodde &
Michel, 1999).
Though the majority of muscarinic receptor activation on cardiac function occurs
via M2, it has recently been noted that M3 receptor activation can have a role at the level
of the cardiomyocyte (Wang et al., 2012). Although M3 receptors are mainly expressed
in vascular endothelium, M3 activation has been highlighted for its regulation and
maintenance on heart function (Gordan et al., 2015). Cardiac M3 receptors are coupled to
a delayed rectifier K+ channel, which ultimately leads to hyperpolarization and a decrease
in heart rate. (Wang et al., 2012). In both guinea pig and canine cardiomyocytes,
researchers have found this K+ current, stimulated by pilocarpine, to be inhibited with
antagonists specific for M3 receptors (Dhein et al., 2001). In addition, while
simultaneously antagonizing M2 receptors, decreasing chronotropic effects seen with
pilocarpine were able to be suppressed with use of M3 antagonist, 4-DAMP (Dhein et al.,
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2001). It has also been discovered that ACh produces a biphasic response, a negative and
positive inotropic response, as a result of varying receptor actions in mice left atria
(Nishimaru et al., 2000). The positive response found was inhibited by a specific
antagonist for M3 receptor, suggesting a role of M3 receptors in cardiomyocytes
(Nishimaru et al., 2000).

1.4.1 Cholinergic Signaling and Transmission
Acetylcholine is synthesized by choline acetyltransferase (ChAT) within a cell,
primarily near the nerve terminal of cholinergic neurons (Wessler et al., 1999). ChAT
catalyzes ACh from acetyl-CoA and available choline (Wessler et al., 1999). This
reversible reaction is dependent on the concentrations of reagents intracellularly (Jope,
1979). Following synthesis, ACh is stored into secretory vesicles through vesicular ACh
transporter protein (VAChT). Vesamicol, an inhibitor of VAChT, diminishes the release
of ACh following a depolarization, without affecting synthesis or choline uptake (Taylor
& Brown, 1999). Upon depolarization, vesicles undergo exocytosis, releasing ACh into
the synaptic cleft and surrounding tissue where ACh can bind to respective receptors and
elicit a response (Wessler & Kirkpatrick, 2001). Unbound ACh is hydrolyzed by
acetylcholinesterase (AChE) into acetate and choline to prevent further interaction with
its receptor (Wessler & Kirkpatrick, 2001). The high affinity choline transporter (ChT1)
can then reuptake free choline back into the cell. ChT1 is known as the rate limiting step
to the production of ACh (Jope, 1979), although VAChT has been noted for its rate
limiting characteristics as well (Roy et al., 2014). It has been shown that blocking ChT1
with a potent inhibitor, Hemicholinium-3, lowers ACh production during stimulation
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(Taylor & Brown, 1999). The interplay of these enzymes is essential for proper function
and homeostasis of the heart (Figure 1).

1.4.2 Non-Neuronal Cholinergic System
Until recently, cholinergic signaling was thought to be dependent on neuronal cell
types (Beckmann & Lips, 2014). That is, activation of the vagal reflex provides direct
communication between peripheral cells via parasympathetic signaling, utilizing ACh.
Both muscarinic and nicotinic receptors are expressed along pre- and post-synaptic
neurons (Eglen, 2006). Specifically, at the level of the cardiac cell, activation of these
receptors causes a decrease in chronotropic and ionotropic parameters. In addition to the
role of controlling heart rate and contractility, vagal stimulation has been known for its
protective qualities (Nuntaphum et al., 2018). By increasing vagal stimulation in rat
models of heart failure, researchers have shown better outcomes than their control
(Rocha-Resende et al., 2012). However, ACh has been highlighted for more than just its
neurotransmitter phenotype. Not only are cholinergic receptors expressed in neuronal cell
types, but in non-innervated tissue (Eglen, 2006; Beckmann & Lips, 2014). Therefore,
ACh has actions outside of the neuronal background, as it can act in an autocrine and
paracrine manor on non-innervated tissues, similar to hormones (Wessler et al., 2001).
Non-neuronal cholinergic expression has been shown in epithelial, endothelial, immune,
mesenchymal and brain tissue, providing an alternative source of ACh (Kawashima &
Fujii, 2008; Beckmann & Lips, 2014). This non-neuronal ACh can affect gene expression
proliferation, differentiation and electrical activity downstream (Wessler et al., 2001).
These cells are capable of synthesizing and releasing ACh independent of neuronal
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Acetyl-CoA
+
Choline

ChAT

ACh

VAChT

(1)
ACh
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Axon Terminal
ACh
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AChE
(2)

Postsynaptic Cell

ACh

ACh
ACh

ACh-R

Figure 1. Interplay of cholinergic enzymes for ACh transmission.
Production of acetylcholine through ChAT (1), the uptake and storage of ACh into
synaptic vesicle through vesicular acetylcholine transporter (VAChT), the release into the
synaptic cleft, where ACh binds to its respective receptor (ACh-R), the hydrolysis of
unbound ACh into choline and acetate through acetylcholinesterase (AChE) (2), the
uptake of choline back into the cell through high affinity choline transporter (ChT1) (3).
Adapted from Pearson Education Inc.
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enzymes, as non-neuronal tissue express necessary enzymes (Wessler & Kirkpatrick,
2009). In addition, reagents for the production of ACh, acetyl-CoA and choline, are
present in nearly all cell types (Wessler & Kirkpatrick, 2009).
Recently, it has been discovered that cardiomyocytes are capable of independently
synthesizing ACh (Rana et al., 2010). These cells possess appropriate enzymes needed
for ACh transmission to occur (Rocha-Resende et al., 2012). ACh then acts in an
autocrine and paracrine manner. This release by cardiomyocytes is dependent on VAChT
expression, as hypertrophic effects were exhibited when VAChT was knocked out in
cardiomyocytes (Rocha-Resende et al., 2012). The intrinsic ability to independently
synthesize ACh can also be considered a defense mechanism against insults and injury
(Rocha-Resende et al., 2012). In addition to the synthesis and eventual release of ACh,
non-neuronal tissues express cholinesterases responsible for hydrolyzing ACh to
diminish its response (Wessler et al., 2001; Kawashima & Fujii, 2008). This widespread
hydrolyzing activity prevents non-neuronal ACh from circulating throughout the body,
like a hormone (Wessler et al., 2001). However, if this activity is inhibited, prolonging
the response of ACh on its respective receptors, cholinergic signaling increases.

1.5 Heart Failure and Altered Cardiovascular Health
Imbalances of autonomic control causes dysfunction of the cardiac system. When
the heart is unable to provide proper blood flow to peripheral tissue, indicating a decrease
of cardiac output, stretch and pressure receptors found in the vasculature sense a change
of activation, leading to an increase in sympathetic signaling to compensate (Gordan et
al., 2015). In addition, the renin-angiotensin-aldosterone system (RAAS) and vasopressin
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are also increased to maintain proper blood flow (Crowley et al., 2006). Ultimately, fluid
retention due to increased reabsorption of both sodium and water increases
vasoconstriction and cardiac stimulation (Fenton & Burch, 2007). This is why heart
failure patients often experience congestion due to increased fluid volume and cardiac
filling (Fenton & Burch, 2007). During periods of ischemic stress, the cardiovascular
system undergoes remodeling processes for protection; however, this can worsen the
outcome (Azevedo et al., 2016). In healthy patients, cardiac output is maintained through
adrenergic activation, causing vasoconstriction (Sukoyan et al., 2017). In heart failure,
this resistance causes a decline in cardiac output as there is an eventual increase in
afterload, inducing more stress on the heart (Sukoyan et al., 2017)

1.5.1 Mechanisms of Heart Dysfunction
Dysfunction of the heart can be defined through both cellular and molecular
mechanisms. Excitation-contraction coupling (ECC) has been noted for its
dysfunctionality in HF (Mihl et al., 2008). More specifically, activity of the sarcoplasmic
reticulum (SR) and its ability to cause an increase in intracellular Ca2+, as well as the
active transport of Ca2+ back into the SR following contraction, is declined in heart
failure (Fenton & Burch, 2007). Moreover, constant exposure of β-AR to increased
sympathetic activity in response to a decreased cardiac output occurs to maintain
homeostasis. This increases cardiac output short term; however, β1 receptors eventually
downregulate and deactivate, preventing cardiac tissue from responding to increases in
sympathetic activity, inducing a feedback loop (Gavioli et al., 2014). Lastly, both
inflammatory markers and natriuretic peptides have been noted in the progression of
heart failure (Mann, 2002). Stress or injury causes a release of neuro-hormones, cytokines
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or free radicals that are able to induce changes in gene expression, modulated by the
transcription factor Nf-κB (Mann, 2002). Increasing gene expression of pro-inflammatory
makers, such as tumor necrosis factor (TNF) alpha, interleukin (IL)-1 and IL-6 are known
to cause myocyte hypertrophy and apoptosis, decreasing cardiac function (Yndestad et
al., 2006). As well, hypertrophied hearts with ventricle dysfunction have been shown to
produce increased levels of brain natriuretic peptide (BNP), which causes ventricular
relaxation, promoting increases in filling (Fenton & Burch, 2007). BNP is produced by
ventricular cells in response to excessive stretching (Gordan et al., 2015). The heart also
produces atrial natriuretic peptide (ANP), which is released by atrial tissue. ANP blocks
excessive catecholamine activity and can inhibit hypertrophic responses by blocking
catecholamine protein synthesis (Gordan et al., 2015). ANP is also protective as it has
been shown to prevent cardiac fibrosis following ischemic injury (Gordan et al., 2015).

1.5.2 Heart Failure as a Progressive Model
A progressive model is commonly used to explain heart failure and the
mechanisms that contribute to its development (Mann, 2002). Recently, neuro-hormonal
pathways have been noted to be a main cause. This neuro-hormonal progression states
that when there are higher concentrations of circulating biological molecules, they are
capable at affecting heart function (Mann, 2002). For example, NE, angiotensin II and
TNF have been noted to contribute to disease progression in cardiovascular health (Mann,
2002). That is, constant exposure to sympathetic neurotransmitters can lead to cardiac
dysfunction.
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It is well known that in heart failure models, there is excessive activation of
sympathetic signaling, modulating the neuro-hormonal response. Acute sympathetic
over-activation, initially compensatory, can cause adverse effects such as myocardial
infarctions and arrhythmias, where chronic activation can lead to hypertension or heart
failure (Manolis et al., 2014). It is unclear whether sympathetic overdrive is the cause or
consequence of these CV diseases.
Initially, the increase in sympathetic signaling is a compensatory response to a
damaging myocardium in order to maintain cardiac output and blood pressure (Nolan et
al., 1992). Increased stress on the cardiovascular system, causes an increase in
catecholamine release to initiate hypertrophic responses and preserve heart function
(Madamanchi, 2007). This is also known as hyper-functional cardiac hypertrophy (Dhalla
et al., 1996). The transition from hyper-functional to decompensated hypertrophy may be
a result of increased oxidative stress due to increases in free radicals or deficits of
endogenous antioxidants, leading to contractile dysfunction (Dhalla et al., 1996).

1.5.3 Changes in Sympathetic Signaling in Heart Failure
Cardiovascular disease can arise due to the imbalance of communication within
the ANS. An increase of sympathetic drive accompanied by a decrease in
parasympathetic signaling typically occurs as heart failure develops (Gordan et al., 2015).
This overdrive of sympathetic signaling increases myocardial oxygen demand and
oxidative stress on the heart; leading to pathological mechanisms known to induce
cardiovascular damage (Giordano, 2005). With increases in catecholamine levels
circulating in heart failure patients, β1 receptors are shown to be downregulated by at
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least 50%, where β2 receptors remain constant (Madamanchi, 2007). This leads to the
impaired ability to regulate autonomic communication, continuing this cycle.
Moreover, it is well known that cardiac hypertrophy precedes heart failure. As
mentioned earlier, myocardial hypertrophy occurs initially to preserve cardiac function.
This adaptive process occurs in response to cardiovascular insults (Dhalla et al., 1996).
Eventually, hypertrophied hearts undergo dysfunction, activating the SNS to maintain
cardiac output. With an increase in sympathetic activation, there is a progressive rise in
afterload, further decreasing heart function (Nolan et al., 1992). Hypertrophic responses
were prevented by decreasing sympathetic activity with pharmaceuticals or transgenic
models (Roy et al., 2013). Desensitization of β1-AR, through increased catecholamine
levels and hypertrophic pathways leads to loss of contractility (Madamanchi, 2007).
Heart rate variability (HRV) has been noted as an indicator of cardiac dysfunction
(Behling et al., 2003). Heart failure models are shown to have decreased HRV, an
indication of increased sympathetic signaling and decreased vagal tone (Nolan et al.,
1992). However, the body attempts to compensate the increase in sympathetic activity,
seen in heart failure, in order to maintain autonomic homeostasis. In heart failure rodent
models, researchers saw adrenergic neurons transdifferentiating into cholinergic neurons
via a gp130-signaling mediated pathway (Kanazawa et al., 2010). This adaptive plasticity
can protect against excessive sympathetic output (Kanazawa et al., 2010).

1.6 Treatments for Heart Failure Patients
To successfully treat heart failure, multiple therapies, characterized by varying
mechanisms of action, are needed to accommodate the wide range of cardiovascular
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pathologies. Therapies for heart failure patients are commonly focused on reducing heart
rate, cardiac overload and remodeling (Sukoyan et al., 2017). These treatments primarily
focus on the higher sympathetic activity typically seen in heart failure. However, it has
become recently apparent that perhaps re-establishing parasympathetic signaling,
commonly decreased in heart failure, may serve as an alternative target. Highlighted here
are autonomic targets for the treatment of HF, as imbalances of autonomic transmission
significantly affect heart efficiency.

1.6.1 Beta Adrenergic Targets
Past and current treatments for heart failure focus on preventing the increase in
sympathetic drive and maintaining proper blood flow and body fluid volume (Sabbah,
2004). Treatments such as diuretics, ACE inhibitors, digoxin and most commonly used βAR blockers focus on reducing heart rate, cardiac overload and remodeling (Fenton &
Burch, 2007; Sukoyan et al., 2017). By preventing the increase in sympathetic activity,
these drugs can decrease myocardial thickening and fibrosis, remodeling and can reverse
the down-regulation of autonomic receptors (Fenton & Burch, 2007). β-AR blockers
reduce effects of the endogenous hormone epinephrine to slow heart rate, contractility
and decrease blood pressure (Barrese & Taglialatela, 2013). This will ultimately lower
the prevalence of arrhythmias and improve contractility (Gheorghiade et al., 2003). Beta
blockers were of high demand due to its ability to compensate for the over activity of
sympathetic output; however, there has been contradictions regarding this treatment of
choice (Barrese & Taglialatela, 2013)
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1.6.2 Cholinergic Targets
Although sympathetic and parasympathetic communication is thought as
opposing forces, the combination of the two, working in unison, controls cardiovascular
health (Gordan et al., 2015). When activated, the parasympathetic system inhibits effects
of sympathetic communication, and vice versa. At rest, the heart is under the influence of
parasympathetic activity, known as vagal tone (Olshansky et al., 2008). As well, HRV, a
crucial measure of cardiovascular health, is dominated by parasympathetic activity (Just
et al., 2000). When the heart is receiving high activation from the sympathetic system,
discharge from the vagus nerve will over ride this, reintroducing balance between
autonomic communication (Olshansky et al., 2008). Using this knowledge, current
treatments are now being investigated and highlighted, moving toward cholinergic
focused interventions. Renewing a balance between the interplay of autonomic
communication may prevent adverse effects of hyper-active sympathetic signaling, seen
in heart failure.
It was not until recently that the cholinergic system had been highlighted for its
cardioprotection. Cholinergic pathways are of interest as it has been shown that
cholinergic trans-differentiation of sympathetic neurons has been seen in heart failure,
indicating the dependence of ACh signaling as a compensatory mechanism (Kanazawa et
al., 2010; Rocha-Resende et al., 2012). As well, it has been previously shown that when
cAMP levels are increased, due to activation of adrenergic receptors, expression levels of
ChAT, VAChT and M2 receptors in cardiac cells also increase, once again suggesting a
compensatory mechanism in response to cardiovascular insults (Rocha-Resende et al.,
2012). Interestingly, mouse models lacking M2 receptors were found to have increased
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cardiac stress (Prado et al., 2013). Instead of focusing treatment on inhibiting adrenergic
and sympathetic actions, increasing cholinergic communication may provide better
outcomes, as it is mimicking physiological autonomic responses.

1.6.2.1 Vagus Nerve Stimulation
Extensive research has been conducted on vagus nerve stimulation and its ability
to provide protection against ischemic reperfusion injuries. A study using a large animal
model of ischemic reperfusion injury suggests vagal stimulation protection was due to
attenuation of mitochondrial dysfunction, as treatment was able to reduce infarct size in
heart tissue (Nuntaphum et al., 2018). Vagal stimulation was also able to decrease total
arrhythmias, preserve left ventricular dysfunction and decrease expression levels of TNFalpha, an inflammatory marker known to induce inflammation and cardiac hypertrophy
(Nuntaphum et al., 2018). Mechanisms involved in cardioprotection through vagus nerve
stimulation post myocardial infarction are independent of heart rate and is regulated
through muscarinic receptor activation, as blocking with atropine, a muscarinic receptor
antagonist, was shown to abolish these effects (Mastitskaya et al., 2012; Gourine &
Gourine, 2014). Chronic stimulation of the vagus nerve has been highlighted as a new
therapeutic treatment for those suffering from heart failure, and may provide beneficial
effects on left ventricular function (De Ferrari et al., 2011). Like previously noted
experiments, researchers have highlighted that protection is independent from HR
changes but most likely a combination of nitric oxide increases, anti-apoptotic and antiinflammatory effects (De Ferrari et al., 2011).
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1.6.2.2 Possible Cholinergic Targets for Treatment
Recently, our lab has focused on the manipulation of cholinergic targets to
investigate its consequence on cardiovascular function. Analyzing these consequences,
researchers are better able to understand the importance of cholinergic expression and the
use for various future treatment measures. When VAChT, a rate limiting step in the
communication of ACh, was chronically knocked down, mice developed heart
dysfunction, with increased cardiac remodeling and altered Ca2+ handling (Lara et al.,
2010). Therefore, with decreased ability to store ACh, release of this neurotransmitter
was also affected, altering autonomic homeostasis. As well, muscarinic receptor
expression was found to be elevated in VAChT knock-down ventricles, showing the
importance of cholinergic expression and transmission in response to a decreased
parasympathetic phenotype, observed in heart failure (Mabe et al., 2006). Specifically in
cardiomyocytes, VAChT deficiency leads to cardiomyocyte hypertrophy and remodeling
(Roy et al., 2013). Recently, a mouse model, initially used to investigate cognitive
applications of increased cholinergic signaling, translated into a model of cardiovascular
health, as increasing cholinergic signaling not only affects cognitive features, but
peripheral as well. This mouse model overexpresses VAChT, a protein responsible for
the packaging and ultimately, the release of ACh from cholinergic cells. Although mice
are negatively affected cognitively from this genotype, their cardiovascular health is
better able to withstand stressors or insults (Kolisnyk et al., 2013; Roy et al., 2016). As
well, when expression of ChAT, an enzyme responsible for the synthesis of ACh, is
decreased, cholinergic signaling coincides. Specifically, ChAT knock out cardiomyocytes
have altered autonomic homeostasis and exhibit hypertrophy and remodeling, like other
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models presented (Roy et al., 2016). These mouse models illuminate the importance of
cholinergic signaling and how targeting specific cholinergic proteins may better able to
treat or prevent the progression of cardiovascular disease.
Cardiac dysfunction has also been seen in models of decreased cholinergic
signaling; specifically, in Muscarinic type 2 (M2) cholinergic receptor knockout mice
(Lacroix et al., 2008). This is the most prevalent cholinergic receptor at the level of
cardiomyocyte and is responsible for the decrease in chronotropic and ionotropic
parameters (Dhein et al., 2001). M2 receptor knockout mice show significant cardiac
dysfunction and remodeling, similar to VAChT knock-down mice (Lacroix et al., 2008).
This mouse model has increased susceptibility to cardiac dysfunction in response to
adrenergic hyper-drive (Lacroix et al., 2008). Although mice have similar cardiovascular
parameters and phenotype to wild-type mice at baseline, when introduced to a stressor,
like adrenergic hyperactivity, M2 knockout mice perform significantly worse, indicating
the importance of ACh transmission during insults (Lacroix et al., 2008).
Moreover, acetylcholinesterase inhibitors, attenuating hydrolysis of ACh and
prolonging its availability in cholinergic nerve terminals and non-neuronal synapses, can
increase cholinergic signaling and may provide protection (Lataro et al., 2015). Currently
used for the treatment of myasthenia gravis, PYR is a reversible peripheral AChE
inhibitor that has been recently noted for its protective abilities. PYR has been shown to
prevent cardiac dysfunction during heart failure, as well as provide protection against ex
vivo and in vivo insults (Durand et al., 2014). In addition, donepezil, a centrally acting
AChE inhibitor, has also been highlighted for its protective effects (Handa et al., 2009;
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Sato et al., 2010). Patients taking donepezil for the treatment of Alzheimer’s show
decreased cardiovascular mortality (Sato et al., 2010).

1.7 Role of Inflammation in Heart Failure
An increase of cytokines in circulation is often found in models of heart failure. In
response to tissue damage, the immune system produces cytokines that are responsible to
promote tissue repair (Rosas-Ballina & Tracey, 2009). Pro-inflammatory cytokines, such
as tumor necrosis factor (TNF) and interleukin (IL)-1, are released in response to
activated macrophages to initiate and progress the inflammatory response (Pavlov et al.,
2003). When the cardiovascular system is introduced to TNFα for a short duration of
time, an adaptive response occurs to properly maintain cardiac output (Ferrari, 1999).
However, chronic exposure to this molecule can cause cardiac dysfunction, as remodeling
and hypertrophy often occur, similar to the cardiovascular response to sympathetic
overdrive (Azzawi & Hasleton, 1999). It is important to maintain proper regulation of
these biochemical processes as over activation of this response can lead to tissue injury
and cardiac hypertrophy (Pavlov et al., 2003; Sukoyan et al., 2017). Anti-inflammatory
markers, IL-10 and IL-4, help to maintain proper tissue repair and counteract prolonged
pro-inflammatory responses (Pavlov et al., 2003).

1.7.1 Cholinergic Control of Inflammation
The autonomic nervous system plays a role in activating or inhibiting the immune
response when exposed to a pathogen or injury. Upon release of sympathetic
neurotransmitter norepinephrine or epinephrine, alpha and β-AR are activated on immune
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cells to cause an increase in pro-inflammatory markers, promoting inflammation (Pavlov
& Tracey, 2005; Kenney & Ganta, 2015). However, it has recently been discovered that
upon release of efferent vagus nerve signals, there is a suppression and inhibition of proinflammatory actions, acting as an anti-inflammatory response (Pavlov & Tracey, 2005).
ACh released from the vagus nerve acts on the α7 subunit of the nicotinic receptor on
macrophages (Rosas-Ballina & Tracey, 2009). It has been shown that upon activation,
release of TNF, IL-beta and IL-6 is inhibited in endotoxin activated macrophages;
however, IL-10 is not affected, confirming anti-inflammatory responses of ACh (Pavlov
& Tracey, 2005; Rosas-Ballina & Tracey, 2009). It has recently been discovered that the
spleen is required for vagus control of the inflammatory pathway (Huston et al., 2006). In
a splenectomy model, vagal stimulation was not able to attenuate the production of TNF
(Huston et al., 2006). As well, the α7 subunit is essential for this anti-inflammatory
response of ACh release (Rosas-Ballina & Tracey, 2009). Furthermore, neuronal and
non-neuronal ACh exert anti-inflammatory effects as they both act at the α7 subunit of
the nicotinic receptor (Wessler & Kirkpatrick, 2009).

1.7.1.2 Biochemical Pathway Involved in Anti-Inflammatory Role of
Cholinergic System
NF-κB is a transcription factor responsible for mediation of inflammatory markers
in response to cytokines (Yndestad et al., 2006). When there is an increase in cytokine
levels, NF-κB is retained to the cytoplasm due to phosphorylation of IκB; however, when
degraded, NF-κB can translocate to the nucleus and induce expression of proinflammatory markers (Rosas-Ballina & Tracey, 2009). In response to ACh signaling
through α7 subunit of nicotinic receptor, protein levels of IκB are increased, leading to
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decreased NF-κB activation, inhibiting expression of TNFα (Rosas-Ballina & Tracey,
2009).
In addition, TNF production can also be suppressed by phosphorylated STAT3, a
process dependent on α7 subunit activity. Upon activation of cytokine receptor, JAK
mediates receptor phosphorylation and STAT recruitment (Rosas-Ballina & Tracey,
2009). JAK phosphorylates STAT while within a receptor complex and STAT-P can then
translocate to the nucleus to induce gene expression of inflammatory markers (RosasBallina & Tracey, 2009). In response to ACh activation of the nicotinic receptor, JAK2 is
phosphorylated and can induce activation of STAT3, which can bind to DNA to induce
anti-inflammatory gene expression, while also inhibiting NF-κB activation of proinflammatory markers. (Rosas-Ballina & Tracey, 2009). NF-κB and Jak/STAT signaling
may both be activated in response to α7 subunit activation and thus, work in unison to
decrease inflammatory marker expression. It has been shown that inhibiting AChE,
increasing available ACh, is inversely related to serum IL-6 and TNF-α levels, and is
found to decrease IL-1 β in brain and blood (Pollak et al., 2005; Rosas-Ballina & Tracey,
2009).

1.7.2 Neural Regulation of Anti-Inflammatory Response
In response to pathogens, tissue injury, or cytokine release, afferents of the vagus
nerve travel to inform the brain of an imbalance of homeostasis. Excessive cytokine
release may extenuate the injury and cause disease (Travey, 2007). Originating in the
dorsal motor nucleus, the efferent fibre of the vagus nerve signals to the celiac-superior
mesenteric plexus, where it is then continued through another neuron, the splenic nerve,
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which terminates at the spleen (Pavlov & Tracey, 2005; Rosas-Ballina & Tracey, 2009).
ACh released by the efferent nerve then acts on the α7 subunit on immune cells, located
around cholinergic nerve terminals, to inhibit pro-inflammatory cytokine production
(Pavlov & Tracey, 2005). This is known as the inflammatory reflex, as neural
connections maintain immune homeostasis in response to injury.

1.8 Rationale and Hypothesis
There has been overwhelming evidence supporting cardiac dependence on
parasympathetic tone. As mentioned earlier, parasympathetic signaling is attenuated in
heart failure (Olshansky et al., 2008). With this, the cholinergic system may serve as an
alternative treatment method to prevent adverse symptoms of heart failure or an
overactive sympathetic drive, such as cardiac remodeling (Roy et al., 2014). In addition,
it is known that cholinergic signaling declines with age, as does cardiovascular function.
Our lab has shown that increasing cholinergic signaling in an aging population can be
protective of cardiovascular health and may attenuate this progression in dysfunction.
Specifically, 3-month old mice that have an overexpression of VAChT in cholinergic
neurons (hyper-VACHT) and wild-type mice show no differences in cardiac function;
however, 18-month old hyper-VAChT mice show significantly less decline in cardiac
function when compared to age-matched wild-type mice (Dakroub, 2015).
To confirm protective effects of the cholinergic system, VAChT was knocked
down in mice, globally decreasing cholinergic signaling (Lara et al., 2010). With
decreased VAChT expression, there is less ACh being released from cells. Mice were
found to develop heart failure, defined by cardiac dysfunction, remodeling and altered
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autonomic control (Lara et al., 2010). These results confirm that parasympathetic
signaling is imperative for proper heart function. Moreover, as cardiomyocytes have been
recently discovered to independently synthesize and release their own ACh, researchers
are better able to manipulate cholinergic signaling at the level of the cardiomyocyte. To
investigate the importance of cardiomyocyte specific cholinergic signaling, researchers
have utilized an animal model where VAChT is exclusively eliminated in mouse
cardiomyocytes using the Cre-LoxP system (Roy et al., 2013). Mice exhibited altered
heart rate activity during periods of stress, indicating cholinergic dysfunction as
parasympathetic signaling is essential during sympathetic overdrive (Roy et al., 2013).
This was also seen in animal models where ChAT was knocked out in cardiomyocytes
(Roy et al., 2013). Once again confirming that non-neuronal parasympathetic signaling
plays an important role in cardiac homeostasis. As well, cardiac hypertrophy, remodeling,
and left ventricular cardiac dysfunction was identified in these knockout mice (Roy et al.,
2013). It is recognizable that maintenance of cholinergic tone is crucial for regular heart
function and the elimination has detrimental effects on cardiovascular homeostasis.
Conversely, researchers utilized a transgenic animal model where VAChT was
overexpressed in cholinergic neurons. Enhanced cholinergic tone did not affect baseline
cardiovascular function; however, due to increased parasympathetic control, increases in
heart rate during exercise were better maintained in comparison with control (Roy et al.,
2016). Mice also displayed less myocyte stress due to increased ACh levels (Roy et al.,
2016). This confirms cardiac derived ACh may lead to greater heart control during
sympathetic overdrive (Rocha-Resende et al., 2012).

24
It has been well shown that the cholinergic system has an imperative role in the
maintenance of heart function and homeostasis. Moving to more clinical applications,
pharmacological agents associated with increasing cholinergic signaling have been found
to share similar results. ACh is hydrolyzed by AChE into choline and acetate in the
surrounding synapse and circulatory pathways. By inhibiting this process and prolonging
ACh transmission, cholinergic signaling is upregulated. It has been noted that donepezil,
a centrally acting AChE inhibitor, was able to attenuate cardiac remodeling in heart
failure models (Handa et al., 2009). Another cholinesterase inhibitor, pyridostigmine
(PYR), is a reversible AChE inhibitor, and has been shown to increase peripheral
cholinergic tone. Being a peripherally acting drug, it is unable to cross the blood brain
barrier and thus, works primarily at the peripheral synaptic clefts. This drug has been
found to decrease the prevalence of left ventricular dysfunction and cardiac hypertrophy
due to increased transmission associated with the inhibition of ACh hydrolysis (Lataro et
al., 2013).
Heart failure is typically accompanied by an overactive sympathetic drive
consequently, leading to myocardial dysfunction. Increased sympathetic drive induces
stress on cardiomyocytes, increasing the risk of injury and remodeling. PYR has been
shown to inhibit this increase in sympathetic drive, by increasing cholinergic tone (Lataro
et al., 2013). By increasing ACh, muscarinic receptors found on pre-synaptic sympathetic
neurons can inhibit the release of NE, further preventing the progression of cardiac
remodeling post myocardial infarction, attenuating cardiac dysfunction that typically
occurs (Triposkiadis et al., 2009; Lataro et al., 2013; Durand et al., 2014).
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The focus of this study is to continue the search for de novo treatment to target
cardiovascular disease. I was interested in investigating whether drug therapy can provide
similar cardioprotection as seen in mice overexpressing VAChT in cholinergic cells. As
well, investigating the neuronal and non-neuronal cholinergic signaling pathways and
whether amplifying cholinergic tone through pharmacological intervention can provide
protection against adverse cardiac symptoms or maintain cardiac homeostasis in response
to insults.
It is hypothesized that acetylcholinesterase inhibition will increase cholinergic
tone and consequently, provide protection to better maintain cardiovascular homeostasis
in response to insults.

1.9 Objectives
1) To show protection in hyper-VAChT mice against ex vivo insults.
2) To determine whether pharmacological treatment with acetylcholinesterase inhibition
can protect the heart against ex vivo insults.
3) To determine the effect of acetylcholinesterase inhibition in vivo during baseline
cardiovascular conditions.
4) To determine the effect of acetylcholinesterase inhibition in vivo in a hypersympathetic model.
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Chapter 2
2 METHODS
2.1 ChR2+ Animal Model
Previously described and published in detail (Ren et al., 2011; Kolisnyk et al.,
2013; Roy et al., 2016), ChAT-ChR2-EFYP mice (The Jackson Laboratory) were used as
a transgenic model of hyper-cholinergic signaling. Briefly, ChAT-ChR2-EFYP mice
express bacterial artificial chromosome (BAC) that has cholinergic locus under control of
ChAT promoter. The channelrhodopsin-2 (ChR2+) protein gene disrupts the
overexpression of ChAT due to the presence of BAC. VAChT gene, contained in the
cholinergic locus, is untouched by the disruption; therefore, cholinergic cells have
increased expression of VAChT (Kolisnyk et al., 2013). These mice were used to
evaluate ex vivo cardiovascular function in response to insults. Present experiments refer
to this model as “Hyper-VAChT” mice.

2.2 Langendorff Perfused Assay
The Langendorff perfused heart assay allows for ex vivo manipulation of an
isolated perfused heart. Filtered Krebs – Heneseleit (KH) solution, pH 7.4, was drawn up
through a peristaltic pump and a heated coil ensured the solution was warmed to 37 °C.
An aerator was placed in the stock solution of KH, which was attached to a 95% O 2 and
5% CO2 pressure tank. The glass jacket surrounding the coil was connected to a
thermocirculator, which keeps the coil heated. The solution was passed through a
pressure transducer and then through a needle cannulating the aorta. Coronary effluent
from the heart was collected in a beaker. A 5.0 silk braided suture (Ethicon, Markham,
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Ontario) was placed through the apex of the heart and attached to a FTO3 Force 34
Displacement Transducer (Grass Technologies, Warwick, RI), placed underneath the
heart. As the heart contracts, the transducer is pulled up vertically and is recorded. Both
contractility (force displacement), heart rate data and coronary artery pressure
measurements were computed through the DI-720 Data Acquisition System (DATAQ
Instruments, Akron, OH) and analyzed using WinDaq (DATQ Instruments, Akron, OH)
and LabChart (ADINstruments, Colorado Springs, CO) software.
For heart extraction, 8 –10-week-old mice were injected with 600 IU/kg of
heparin, 10 minutes prior to sacrifice to reduce risk of blood coagulation in the coronary
arteries and euthanized through a cervical dislocation. The chest cavity was opened and
the heart was extracted. The heart was then placed in ice cold KH solution pH 7.4 that
was previously oxygenated with 95% O2 and 5% CO2. The surrounding connective and
lung tissue was removed and the aorta was isolated making sure to leave at least two
centimeters intact. The cannulating needle was pushed through the aorta, being careful
not to disrupt the valves. A silk suture was then tied around the aorta, securing the heart
onto the needle. A 5.0 silk braided suture was passed through the apex of the heart. The
needle and heart were then brought to the Langendorff apparatus and secured
downstream of the in-line pressure transducer. The suture through the apex was then tied
off around the force displacement transducer. This was preferably done under 5 minutes
to minimize damage. The cannulated aorta is subject to continuous flow at 2 mL/min.
This reverse perfusion or retrograde perfusion causes pressure to build up at the aortic
valve, forcing it to close. The perfusate is directed into the coronary arteries, supplying
the heart with oxygen and nutrients. Venous return then drains from the coronary sinus to

28
the right atrium, where effluent is then ejected into the right ventricle and out the
pulmonary artery. Due to extraction and cleaning of connective tissue, the pulmonary
artery is severed allowing the effluent to drip from the heart.
Ischemic reperfusion (IR) injury was performed on hearts connected to the
apparatus. Once hearts were secured, a 20-minute stabilization period established the
baseline heart rate and contractility. Ischemia is the cessation of oxygen and nutrients to
the heart. The peristaltic pump was shut off for 15 minutes and the heart was able to beat
without flow of perfusate. After ischemic period is over, the pump was returned to
normal flow, as the oxygenated perfusate is reintroduced to the heart, indicating the
reperfusion phase. Hearts are then perfused for 60 minutes. Damage from IR injury is
accumulated through both phases. During ischemia, ATP and pH levels drop due to
anaerobic metabolism. This causes ATP dependent mechanisms to become dysfunctional,
such as intracellular Ca2+ concentrations due to altered ion transporters (Sanada et al.,
2011). During the reperfusion phase, the sudden increase in oxygen due to restoration of
perfusate flow causes an accumulation of reactive oxygen species (ROS), which then
induces pro-inflammatory neutrophils to infiltrate, exacerbating the injury (Sanada et al.,
2011). I was interested in quantifying the amount of necrotic tissue accumulated from the
ischemic injury. We performed these experiments with Hyper-VAChT and wild type
mice, and wild-type hearts treated with PYR, an acetylcholinesterase inhibitor, to
evaluate protection from increased cholinergic signaling. PYR was introduced to the
Langendorff apparatus during the ischemic period at a final concentration of 100 μM.
Perfusate was recycled throughout the protocol.
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2.3 Quantification of Necrosis Following IR Injury on Langendorff
Necrosis was quantified following the reperfusion phase of the protocol. Hearts
were removed and horizontally sliced into 4–5 sections roughly the same size. Slices
were then placed in 1% 2,3,5-triphenyl tetrazolium chloride (TTC) in phosphate buffer
solution (PBS) warmed to 37 °C. Slices were stained for 20 minutes, continuously
agitating and maintaining temperature. Slices were then washed with warmed phosphatebuffered solution and placed in 10% formalin for five minutes. Slices were then placed on
a glass plate and imaged using the Nikon Digital Sight connected to the Nikon SMZ800
microscope. ImageJ software (National Institutes of Health, Bethesda, MD) was then
used to analyze the images. Necrotic tissue, shown as pale white, was quantified as a ratio
of necrotic tissue to the total area of tissue slice. Black and white images were made to
better present necrotic tissue and total area. TTC stain differentiates metabolically active
tissue from inactive tissue. Dehydrogenases reduce TTC to a red 1,3,5triphenylformazan (TPF) in the presence of NADH. The enzymatic pathways no longer
work in damaged tissue and necrotic tissue remains pale (Burdock et al., 2011).

2.4 Animal Models and Drug Administration
To examine the effects of sustained PYR (Sigma-Aldrich, Mississauga, Canada)
treatment during baseline conditions, Alzet osmotic pumps (Model 1004, Durect
Corporation, USA) were surgically implanted in mice at 1 mg/kg/day or saline as vehicle
for four weeks. Mice were maintained in the Animal Care Facility at Western University
(UWO, London, Canada). All experiments performed on animals followed the guidelines
and protocols approved by the University Council on Animal Care for animal research.
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To investigate the effect of PYR treatment in response to hyper-sympathetic
activity, commonly seen in heart failure, experiments were performed using 8-10-weekold male wild-type C57BL6/J mice treated with isoproterenol (ISO) (Sigma-Aldrich,
Mississauga). ISO was injected at 60 mg/kg/day or saline for seven days using
intraperitoneal injections and were maintained in the Animal Care Facility. PYR (1
mg/kg/day) or saline was then infused through Alzet Osmotic Pumps (Model 2002,
Durect Corporation, USA) for two weeks. A schematic diagram is shown in Figure 2
depicting the timeline of protocol.

2.5 Echocardiography
Two-dimensional guided M-mode echocardiograms were performed on both
control and treated isoflurane-anesthetized mice to assess cardiac function under noninvasive conditions as previously described (Lara et al., 2010). Left ventricular internal
diameters (LVID), ejection fraction (EF), fractional shortening (FS), and ventricular
anterior (LVAW) and posterior (LVPW) wall thickness was measured using Vevo 2100
ultrasound imaging system (Visual Sonics, Canada) during systole and diastole.
Measurements were obtained using a short-axis view. M-mode cursor was placed
perpendicular to the left ventricular anterior and posterior walls. Ejection fraction was
calculated as EF (%) = [(LVIDd)3 – (LVIDs)3]/(LVIDd)3 x 100. Fractional shortening
was calculated as: FS (%) = (LVIDd – LVIDs)/LVIDd x 100. Measurements were
averaged from three cardiac cycles.
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Figure 2. Experimental timeline for acetylcholinesterase inhibition in a hypersympathetic model.
Mice were treated with ISO (60 mg/kg/day) or saline for one week through
intraperitoneal injections. Respective mice were then treated with either PYR (1
mg/kg/day) or saline for an additional two weeks through mini-osmotic pumps. Mice
were then sacrificed and tissues were analyzed. The schematic above shows the timeline
and specific experiments performed during the duration of protocol. Green arrow
represents when injections started. Red arrow represents when injections ended. Purple
arrow represents when osmotic pumps were surgically implanted subcutaneously into
mice. Yellow arrow represents when mice were sacrificed.
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2.6 Metabolic Assessments
Experiments were performed using the Comprehensive Lab Animal Monitoring
System (CLAMS) (Columbus Instruments) previously described and published (Guzman
et al., 2013; Kolisnyk et al., 2013). Mice were housed in individual chambers (2730 cm3)
maintained at 24 ± 1 ºC with airflow of 0.5 L/min and were allowed access to powdered
standard rodent chow and water throughout the duration of protocol. Measurements were
taken every 10 minutes for 24 hours after a 16-hour habituation period. Oxygen
consumption (VO2) and carbon dioxide excretion (VCO2), food and water intake, activity
and inactivity (sleep) was measured over a 12-hour light/dark cycle in the X- and Y- axis,
respiratory exchange ratio (RER) was calculated from VCO2/VO2. All measurements
were performed within the Oxymax software. Activity and inactivity was calculated
using Opto-M3 Activity Monitor through Oxymax software as previously described
(Guzman et al., 2013).

2.7 Quantitative Real-Time Polymerase Chain Polymerase (RT-PCR)
Whole heart tissue was isolated and total RNA was extracted using the Aurum
Fatty and Fibrous Tissue RNA Extraction Kit (Bio-Rad Laboratories, Mississauga,
Canada) according to the manufacturer’s protocol. Heart tissue was eluted in 80 μL of
Elution Solution provided in extraction kit. Total RNA was then tested for quality and
quantity through microfluidic analysis using Agilent 2100 Bio analyzer (Agilent
Technologies Inc., Palo Alto, CA). Using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Streetsville, Canada), 20 μL of cDNA was
synthesized from 500 ng of total RNA through reverse transcription following the
manufacturer’s protocol. cDNA then underwent qPCR on ViiA 7 Real-Time PCR System
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(Applied Biosystems, Streetsville, Ontario) using the RT2 SYBR Green ROX qPCR
Mastermix (Qiagen, Mississauga, ON, Canada). The PCRs were cycled 40 times after
initial denaturation (95°C, 10 min). Following denaturation, samples were cycled at 95°C
for 15 seconds, with annealing and extension at 60°C for one minute. A non-template
reaction was run as a negative control. Relative mRNA levels of VAChT, ChT1, AChE,
ANP, Myh7, Adrb1 and Chrm2 were normalized to β-actin. All primers used were
validated before use to confirm efficiency. Relative quantification of gene expression was
done using the DDCT method.

2.8 Histological Analysis
Five μm thick sections were obtained from treated mice. Experimental
protocol is shown in Figure 2. Tissues were stained with hematoxylin and eosin (H&E)
using standard procedures. Light microscopic images were captured at 20x and 40x
magnification at quadrants within the left ventricular wall. Cardiomyocyte cross sectional
area was measured using H&E stained sections.

2.9 Cardiac Fibrosis
Five μm thick sections were obtained from treated mice. Tissues were stained
with Trichrome C using standard procedures and light microscopic images were captured
at 20x to analyze interstitial and perivascular cardiac fibrosis. Total fibrotic area within
these images was quantified as a percent of total area.
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2.9 Heart Rate and Blood Pressure Recording
Heart rate and blood pressure was recorded using the non-invasive CODA
tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) on conscious
mice as previously described (Beraldo et al., 2013; Tutunea-Fatan et al., 2018). Sessions
of recorded measurements occurred throughout the protocol. Each session included two
sets of 10 measurements.

2.10 AChE Activity and ACh Concentration Fluorescence Quantification
AChE activity and ACh concentration was measured using the Amplex™
Acetylcholine/Acetylcholinesterase Assay Kit (ThermoFisher Scientific, Waltham, MA)
as previously described (Schallreuter et al., 2004) and following the provided protocol.
Briefly, whole blood or heart tissue was collected and spun down at 12,000 RPM for 15
min at 4 ºC or homogenized and then spun down, respectively. Heart tissue was
homogenized in 500 μL lysis buffer. Further, heart tissue and plasma were diluted 1:10
and 1:50, respectively. Amplex red agent is a sensitive probe for hydrogen peroxide.
AChE hydrolyzes ACh to choline, which is oxidized by choline oxidase to hydrogen
peroxide and other products. Hydrogen peroxide, in the presence of horseradish
peroxidase, reacts with the Amplex red agent to generate resorufin. This highly
fluorescent product can be detected on a fluorescence microplate reader. ACh levels were
also detected using this kit. Enzyme activities were quantified using a fluorescence
spectrophotometer using an excitation range of 530–560 nm and emission detection at
590 nm.
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2.11 ELISA Analysis for TNF-α and IL-6
Pro-inflammatory marker levels of TNF and IL-6 were quantified using an
ELISA analysis. A sandwich colorimetric ELISA was done to evaluate TNF levels in
plasma using the Mouse TNF alpha ELISA Kit (ab208348; Abcam, Cambridge MA,
USA); sensitivity 9.1 pg/mL; range 46.88 pg/mL – 3000 pg/mL. IL-6 pro-inflammatory
markers were quantified in plasma using the Mouse IL-6 ELISA Kit (Interleukin 6)
(ab100712); colorimetric; sensitivity < 2 pg/mL; range 0.82 pg/mL – 600 pg/mL. Assays
were done according to the manufacturer’s instructions.

2.12 Statistical Analyses
Results for all experiments are provided as mean ± S.E.M. Statistical differences
were calculated with either a Student’s t-test, one-way-ANOVA with Tukey’s post-hoc
test, or chi-squared test were used between experimental groups. P < 0.05 was considered
statistically significant. GraphPad Prism was used for all statistical analysis.
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Chapter 3
3 RESULTS
To demonstrate the protective effects of ACh in response to injury, an ex vivo
model of ischemic reperfusion injury was used. Previously, it was shown that age is
associated with a progressive decline of parasympathetic signaling, as aged mice are less
able to maintain their cardiovascular function in response to an injury, compared to
younger mice (Dakroub, 2015). When cholinergic signaling was re-established, mice
were better able to withstand cardiovascular damage. This ex vivo model was used to
determine potential protective effects of ACh and how cholinergic signaling can protect
or prevent cardiac damage.

3.1 Hyper-VAChT mice show protection against ex vivo cardiac injury.
An ex vivo technique, known as a Langendorff assay, was used to quantify
the decline in cardiac function following an ischemic reperfusion injury. Hearts were then
stained with tetrazolium chloride to allow for the delineation of myocardial infarction or
necrotic tissue. To confirm protection, hyper-VAChT and wild-type mice were used.
Hyper-VAChT mice have a 3-fold increase of VAChT expression (Dakroub, 2015).
When quantifying the maintenance of cardiac function in response to ischemic
reperfusion injury, hyper-VAChT mice present significantly less declines in heart rate
(%) compared to its control following ischemic reperfusion injury (Figure 3a). In other
words, hyper-VAChT mice were better able to maintain heart function in response to
injury. However, the change of contractility was not significantly different between
genotypes (Figure 3b). This was also seen in previous experiments with age-matched
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Figure 3. Maintenance of cardiac function post ischemic reperfusion injury in
hyper-VAChT mice.
Quantification of the decline in function (%) of a) heart rate and b) contractility following
ischemic reperfusion (IR) injury on wild-type and hyper-VAChT hearts on the
Langendorff perfusion assay. c) Necrosis (%) in respective heart tissue following IR
injury, quantified with tetrazolium chloride staining and d) representative images. n = 4 /
genotype. *P < 0.05. Data are represented as mean ± S.E.M.
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mice (Dakroub, 2015). When quantifying necrotic tissue accumulated post injury, hyperVAChT mice showed significantly less necrotic tissue (%) compared to wild-type mice
(Figure 3c). This data suggests a protective role of increased cholinergic transmission in
hyper-VAChT mice, as they were better able to maintain cardiac function and had
significantly less necrosis post injury compared to wild-type mice.

3.2 ACh concentration and AChE activity in hyper-VAChT mice.
To phenotype hyper-VAChT mice in terms of ACh concentration and AChE
activity, blood was extracted from mice using collection tubes coated with EDTA to
prevent coagulation. ACh levels were found to be significantly higher in plasma from
WT mice compared to hyper-VAChT mice (Figure 4a). However, AChE activity was not
significantly different between phenotypes (P=0.0626) (Figure 4b). A possible
explanation for this observation is the relative balance required to maintain homeostasis
in response to increased cholinergic transmission in hyper-VAChT tissue during baseline
conditions.

3.3 Acute exposure to pyridostigmine protects heart against ex vivo cardiac injury.
Previous experiments confirm that mice overexpressing VAChT show
protection against cardiac ischemic reperfusion injury. I was interested in whether this
protection can be mimicked through pharmacological intervention. Wild-type hearts were
subject to ischemic reperfusion injury on ex vivo Langendorff perfusion assay. Hearts
were either treated with PYR, an acetylcholinesterase inhibitor, or saline, prior to
ischemic period and the change of cardiac function was assessed. Hearts treated with
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PYR were better able to maintain function, indicated by a significantly less decline of
heart rate (%) and contractility (%) compared to control hearts (Figure 5a, b). As well,
necrotic tissue (%) was significantly reduced in hearts treated with PYR (Figure 5c). By
inhibiting its hydrolysis, increases in non-neuronal ACh may be protective against
cardiovascular insults.

3.4 Pyridostigmine treatment has no effect on cardiovascular baseline parameters in
vivo.
In an ex vivo model, PYR was shown to have protective effects against injury in
wild-type mice. To investigate the effect of PYR on baseline cardiovascular parameters in
vivo, mice were treated with PYR at 1 mg/kg/day or saline in mini osmotic pumps for
four weeks. During treatment, there were no significant differences found in blood
pressure or heart rate within treatment groups (Figure 6). These measurements were taken
before treatment, during treatment, and post treatment to identify if PYR influenced
hemodynamic properties. As well, there was no indication of altered cardiac function, as
echocardiographic assessments showed no differences between treatment groups (Figure
7). Administering PYR and inhibiting the hydrolysis of ACh, thereby increasing its
transmission, would cause an expected decrease in chronotropic and ionotropic
parameters; however, as shown in Figure 7, no differences were seen. It is suggested that
there are compensatory mechanisms responsible for cardiac homeostasis during stable or
baseline conditions.
To investigate the effects of increased cholinergic signaling on baseline metabolic
parameters, mice were placed into metabolic chambers and assessed for volume of O 2
inhaled and CO2 exhaled, respiratory exchange ratio, food and water consumption,
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Figure 5. Maintenance of cardiac function post ischemic reperfusion injury in ex
vivo wild-type hearts treated with PYR.
Quantification of the decline in function (%) of a) heart rate and b) contractility following
ischemic reperfusion (IR) injury on hearts treated with 100 μM PYR or saline on the
Langendorff perfusion assay. n = 7–11 / treatment. c) Necrosis (%) in respective heart
tissue following IR injury quantified with tetrazolium chloride staining and d)
representative images. n = 4–5 / treatment. *P < 0.05. Data are represented as mean ±
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Figure 6. Analysis of heart rate and blood pressure in wild-type mice treated with
PYR or saline for 4 weeks.
Wild-type mice were treated with PYR at 1 mg/kg/day or for four weeks. Blood pressure
and heart rates were measured using non-invasive tail cuff blood pressure system.
Analysis was recorded at a) baseline, b) during treatment (2 weeks post-surgery) and c)
end of treatment (4 weeks post-surgery). No significant differences were found between
treatment groups. n = 4 / treatment. Data are represented as mean ± S.E.M.
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Figure 7. Analysis of cardiac function using echocardiograms in wild-type mice
treated with PYR or saline for 4 weeks.
Mice were subject to M-mode echocardiography to assess cardiac function using the
Vevo 2100 ultrasound imaging system (Visual Sonics, Canada). a) Left ventricular
anterior and b) poster wall thickness during systole and diastole. c) Left ventricular
diameters were recorded during systole and diastole. These values were then used to
calculate d) ejection fraction (%) ([(LVIDd)3 - (LVIDs)3]/(LVIDd)3 x 100). No
significant differences were found between treatment groups. n = 4 / treatment. Data are
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activity and inactivity (Figure 8). Interestingly, food consumption was significantly
increased in mice treated with PYR compared to its control during the 12-hour light
period (Figure 8c). This may be due to increased digestion and gastric function in
response to increased levels of ACh. Mice were then sacrificed and their tissues were
harvested. Tissue weights were normalized to their respective tibia length. Body weight
and heart weight were unchanged with PYR treatment (Figure 9). As well, four weeks of
PYR treatment showed no effect on tissue morphometry (Figure 10).
To summarize, present experiments show that overexpression of VAChT
increases cholinergic tone and shows cardio-protection. I have also demonstrated that
PYR, an acetylcholinesterase inhibitor, is a pharmacological agent that can show
protection in response to ex vivo insults. These previous experiments were specifically
investigating the non-neuronal cholinergic system as ex vivo Langendorff assay is
considered void of neuronal innervation. Interestingly, during baseline parameters, PYR
treatment in vivo caused no significant changes to hemodynamic properties and cardiac
function. Further, I was interested in how PYR treatment could show protection against
cardiovascular insults in vivo.

3.5 Isoproterenol decreases hemodynamic parameters after one week of treatment.
I was interested in determining potential protective effects of in vivo PYR
treatment in response to cardiac injury. For this initial cardiac insult, ISO injections were
used. ISO has recently been used as a model of hyper-sympathetic activity. As noted
earlier, an imbalance of autonomic signaling is often seen in heart failure, with
prominence to adrenergic activity. By inducing a state of hypertrophy and/or mild heart
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Figure 8. Metabolic assessment of mice treated with PYR or saline for 4 weeks.
Mice underwent metabolic assessment through Comprehensive Lab Animal Monitoring
System to see the effect of PYR on metabolic activity and inactivity during a 12-hour
light and 12-hour dark cycle. a) Volume of O2 consumed, b) volume of CO2 exhaled, c)
respiratory exchange rate, d) food intake, e) water intake, f) ambulatory movement, g)
total movement, h) sleep. n = 4 / treatment. *P < 0.05. Data are represented as mean ±
S.E.M.
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Figure 9. Heart weight, body weight, and tibia length of mice treated with PYR or
saline for 4 weeks.
Following treatment, mice were sacrificed and tissues were extracted and weighed. a)
heart weight / tibia length, b) body weight, and c) tibia length. n = 4 / treatment. Data are
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Figure 10. Spleen, Lung, and Liver weight normalized to respective tibia lengths of
mice treated with PYR or saline for 4 weeks.
Following treatment, mice were sacrificed and tissues were extracted and weighted. a)
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failure, I would be able to determine if PYR can protect the heart against adverse effects
and/or reverse cardiac insults from ISO treatment. Firstly, mice were treated with ISO at
60 mg/kg/day through intraperitoneal injections for one week. While some literature
reports ISO administration through continuous exposure, the present study utilizes bolus
injections to induce a state of sympathetic hyperactivity. Many hormones found in the
body are secreted in a pulsatile fashion; meaning that there are large increases in
concentration of the molecule during the burst. Administering ISO through injections,
rather than constant exposure, was preferred in order to have a large peak plasma
concentrations in a small duration of time. Although injections of ISO have been shown
to cause the same degree of hypertrophy as continuous administration, the latter is more
likely to cause desensitization more quickly, decreasing its effectiveness (Hohimer et al.,
2005). Hemodynamic properties were shown to be significantly decreased following ISO
treatment. Figure 11 shows a decline in both systolic and diastolic blood pressure, and
heart rate. Noted previously, ISO is a non-selective beta adrenergic agonist, acting at both
β1 and β2 receptors. This data suggests that desensitization is occurring with preference to
β1 receptors, as heart rate is significantly decreased.

3.6 Isoproterenol treated mice show hypertrophic responses in ventricular tissue
and increased levels of pro-inflammatory markers.
Cardiac function was evaluated through echocardiographic measurements.
Although ventricular internal diameters were not significantly different, both anterior and
posterior walls were found to be significantly thicker in mice treated with ISO than with
saline (Figure 12). Ejection fraction and fractional shortening are parameters that are
commonly used to evaluate the efficiency of heart activity. Although not significant
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blood pressures were analyzed using the non-invasive tail cuff system. Changes of a)
systolic blood pressure and b) diastolic blood pressure in response to ISO treatment. c)
Heart rate between treatment groups at baseline and post treatment are shown n = 20–23 /
treatment. ***P < 0.001. ****P < 0.0001. Data are represented as mean ± S.E.M.

50

b)
5

Control

Control

3

2

****

***
****

1

0

c)
80

Ejection Fraction (%)

ISO

4

60
40
20
0

LVIDs

LVIDd

LVAWs

P = 0.063

LVAWd

***

LVPWs

ISO

c)

LVPWd

d)
Fractional Shortening (%)

Left Ventricular Measurements (mm)

a)

40
30
20
10
0

Figure 12. M-mode echocardiographic assessment of cardiac function in mice
treated with isoproterenol for 7 days.
Mice were either treated with ISO or saline for seven days through injections. a) left
ventricular measurements including internal diameter (mm) during systole (LVIDs), and
diastole (LVIDd), anterior wall thickness (mm) during systole (LVAWs) and diastole
(LVAWd), and posterior wall thickness (LVPWs/d). b) Representation of left ventricle in
echocardiogram analysis c) ejection fraction, the amount of blood ejected from the heart,
and d) fractional shortening, a ratio of left ventricle diameters during cardiac cycle. n =
19–24 / treatment. ***P < 0.001. ****P < 0.0001. Data are represented as mean ± S.E.M.
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(P = 0.0631), higher EF and FS values compared to control were predicted, as activation
of adrenergic signaling contributes to a higher cardiac output. When heart tissue is
consistently over stimulated, cardiac hypertrophy can occur. Through echocardiography,
we show increases in ventricular wall thickness in response to adrenergic hyperactivity.
Hypertrophy is usually accompanied or in response to increased inflammatory marker
expression. I quantified the level of pro-inflammatory markers, TNF-alpha and IL-6, in
plasma after seven days of ISO injections. Mice treated with ISO had significantly
increased levels of pro-inflammatory markers, TNF-alpha and IL-6 in plasma, compared
to mice treated with saline (Figure 13).

3.7 Pyridostigmine re-establishes hemodynamic parameters and prevents increases
in heart rate seen in isoproterenol treated mice.
Following one week of ISO or saline injections, mice were then treated with PYR
or saline for two weeks, after which mice were sacrificed for further analysis.
Experimental protocol is shown in Figure 2. Heart rate and blood pressure changes during
the two-week protocol are shown in Figure 14. Following ISO injections, PYR treatment
was able to re-establish or significantly increase both systolic and diastolic blood
pressure, compared to its respective controls. PYR was also able to prevent the increase
in heart rate seen in ISO treated mice (Figure 14c).
AChE activity was measured in both plasma and heart tissue to confirm actions.
As shown in Figure 15a, PYR was able to significantly decrease the activity of AChE in
plasma when compared to control mice. However, when ISO treated mice were then
treated with PYR, AChE activity was not significantly different from the respective
control. This may suggest a protective mechanism in response to ISO treatment alone.
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Figure 13. Quantification of pro-inflammatory markers, TNF-alpha and IL-6 levels
in response to isoproterenol treatment.
Mouse plasma was collected in EDTA coated collection tubes and a) TNF-alpha (pg/mL)
and b) IL-6 (pg/mL) levels were quantified with respective Mouse ELISA kits (Abcam,
Cambridge MA, USA). n = 10–17. *P < 0.05. Data are represented as mean ± S.E.M.
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Figure 14. Effect of PYR treatment following isoproterenol injections on blood
pressure and heart rate recordings.
Mice were injected intraperitoneal with ISO (60 mg/kg/day) or saline for seven days,
followed by two weeks of PYR (1 mg/kg/day) or saline treatment. Heart rate and blood
pressures were analyzed using the non-invasive tail cuff system. a) change of systolic
blood pressure and b) diastolic blood pressure throughout the protocol. c) change of heart
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S.E.M.
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Decreasing AChE activity causes an increase in cholinergic signaling, as it decreases the
extent of ACh hydrolysis, which may explain why there was no significant decreases
seen in AChE activity between ISO and ISO+PYR mice. In heart tissue, like plasma,
PYR was able to significantly decrease AChE activity when compared to control mice;
however, this was not seen in mice treated with ISO followed by PYR (Figure 15b).
These unexpected results suggest a protective mechanism in response to hyper
sympathetic activity. It is worth noting that AChE activity levels, quantified post
sacrifice, are less exaggerated than those in vivo as tissues were diluted and stored prior
to analysis.

3.8 Metabolic parameters in response to isoproterenol and pyridostigmine
treatment.
Mice were then subject to metabolic analysis. Mice were placed in metabolic
chambers and a range of metabolic parameters were measured (Figure 16). The volume
of O2 inhaled and CO2 expelled was measured and used for the calculation of respiratory
exchange ratio (RER). RER is used to determine the fuel source being used to supply
energy. As well, food and water consumption, and sleep were measured. Ambulatory
movements and total movements were also investigated. Ambulatory measurements
indicate movement happening in a particular direction, whereas total ambulatory
movements indicate any type of movement, such as a turn or an ear flick, in addition to
ambulatory movements. This was analyzed within a 12-hour light period and 12-hour
dark period. Activity and inactivity was found to be of interest, as mice treated with ISO
and PYR show higher activity and less sleep than Control+PYR mice (Figure 16). As
well, mice treated with ISO and PYR were found to sleep less than mice just treated with
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Figure 16. Metabolic assessment of mice treated with PYR following ISO injections.
Mice were placed in metabolic chambers and assessed through Comprehensive Lab
Animal Monitoring System to see the effect of PYR on metabolic activity and inactivity
following ISO injections. This was done during a 12-hour light and 12-hour dark cycle. a)
Volume of O2 consumed, b) volume of CO2 exhaled, c) food intake, d) water intake, e)
respiratory exchange rate, f) sleep, g) ambulatory movement, h) total movement. n = 10–
13 / treatment. *P < 0.05. **P < 0.01. Data are represented as mean ± S.E.M.
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PYR. These changes were found specifically during the light 12-hour period, and not the
dark period. In addition, tissue morphometry relative to tibia length was analyzed and no
significant differences were seen (Figure 17). Wet lung to dry lung weight ratio was also
unchanged due to treatment (Figure 17d). Previously, this ratio was shown to be
increased in mice treated with ISO; however, this was not seen in the present study. The
observation may elucidate the differences seen between sacrificing mice immediately
after ISO injections, or post PYR treatment.

3.9 Acetylcholinesterase inhibitor prevents hypertrophy in ventricular tissue in
response to hyper-sympathetic model.
Mice were subjected to echocardiograms to determine the change in cardiac
function in response to PYR treatment. A paired t test was performed on left ventricular
parameters of ISO mice before and after two-week saline treatment. There were no
significant differences found between left ventricular internal diameters, and no change in
ejection fraction or fractional shortening (Figure 18). Before saline pump treatment, mice
treated with ISO for a week were shown to have increased ventricular wall thickness
(Figure 12). After two-week saline treatment, only anterior wall thickness during systole
was found to be decreased when compared to previous measurements (Figure 18). This
may suggest that cessation of ISO treatment alone is protective for cardiac morphology.
Moreover, a paired t test was also performed with ventricular dimensions in ISO+PYR
mice before and after two-week PYR treatment to determine the effect. Despite no
change in internal diameter, there was a significant decline in both anterior and posterior
wall thickness during systole and diastole, in response to PYR treatment (Figure 19). This
suggests that PYR is able to further prevent the hypertrophic response seen in ISO
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Figure 17. Tissue weights and lung wet / dry weight ratios of mice treated with PYR
for two weeks following isoproterenol injections for 7 days.
Following treatment, mice were sacrificed and tissues were extracted and weighed. a)
Spleen weight / tibia length, b) liver weight / tibia length, c) lung weight / tibia length, d)
wet / dry lung weight ratio, e) tibia lengths. n = 10–13. Data are represented as mean ±
S.E.M.
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Figure 18. M-mode echocardiographic assessment of cardiac function in mice
treated with saline for two weeks following isoproterenol injections for 7 days.
Mice were treated with ISO for seven days through injections, followed by treatment with
saline for the following two weeks. A paired t-test was conducted to assess how cardiac
function was affected after two-week saline treated after cessation of ISO injections. a)
Left ventricular internal diameter (mm) during systole (LVIDs), and diastole (LVIDd). b)
ejection fraction, the amount of blood ejected from the heart, and fractional shortening, a
ratio of left ventricle diameters during cardiac cycle. c) Left ventricular anterior wall
thickness (mm) during systole (LVAWs) and diastole (LVAWd), and d) left ventricular
posterior wall thickness (LVPWs/d). n = 10. *P < 0.05. Data are represented as mean ±
S.E.M.
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Figure 19. M-Mode echocardiographic assessment of cardiac function in mice
treated with PYR for two weeks following isoproterenol injections for 7 days.
Mice were treated with ISO for seven days through injections, followed by treatment with
PYR for two weeks. A paired t-test was conducted to assess how cardiac function was
affected by PYR treatment following cessation of ISO injections. a) Left ventricular
internal diameter (mm) during systole (LVIDs), and diastole (LVIDd). b) ejection
fraction, the amount of blood ejected from the heart, and fractional shortening, a ratio of
left ventricle diameters during cardiac cycle. c) Left ventricular anterior wall thickness
(mm) during systole (LVAWs) and diastole (LVAWd), and d) left ventricular posterior
wall thickness (LVPWs/d). n = 13. *P < 0.05. **P < 0.01. ****P < 0.0001. Data are
represented as mean ± S.E.M.
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treatment, in addition to cessation of ISO treatment alone. Ejection fraction was also
shown to be significantly decreased (Figure 19b). This may be contributed to the negative
ionotropic parameters of ACh, ultimately alleviating stress on the heart. This data
suggests that increased cholinergic signaling was able to mitigate the hypertrophic
response seen in response to ISO. It is worth noting that cardiac function in both Control
and Control+PYR mice did not change during two-week saline or PYR treatment.
Previously shown, increased levels of pro-inflammatory markers, IL-6 and TNF
alpha, were found in plasma from ISO treated mice after one week of injections (Figure
13). After the two-week protocol with PYR or saline, inflammatory markers were
quantified again. Consistently, ISO mice were found to have significantly higher levels of
TNF-alpha and IL-6 compared to control mice (Figure 20). This increase was also seen in
ISO+PYR mice when compared to Control+PYR mice. However, when evaluating the
effect of PYR treatment on inflammatory marker levels in ISO treated mice, there was no
significant differences (Figure 20).
Following the two-week treatment of PYR or saline, mice were then sacrificed
and their tissues were harvested. Heart weight, normalized to respective body weight, was
shown to be significantly increased in mice treated with ISO, followed by two-week
treatment of saline, when compared to control mice (Figure 21). Treatment with PYR had
no effect on heart weight.

3.10 Autonomic gene expression and cardiac damage marker levels in response to
isoproterenol and pyridostigmine treatment.
mRNA was extracted from heart tissue and qPCR analysis was performed
to quantify gene expression changes in response to both ISO and PYR (Figure 22). There
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Figure 20. Quantification of pro-inflammatory markers, TNF-alpha and IL-6 in
mice treated with PYR for two weeks following isoproterenol injections for 7 days.
Mouse plasma was collected and TNF-alpha (pg/mL) and IL-6 (pg/mL) levels were
quantified with respective Mouse ELISA kits (Abcam, Cambridge MA, USA). a) TNF
alpha and b) IL-6 levels, respectively, in mice treated with ISO for one week, followed by
PYR or saline treatment for two weeks. n = 3–11. Different letters represent statistically
significant differences. “a” is significantly different from “b” but not “ab”. “b” is
significantly different from “a” but not “ab”. “ab” is not significantly different from “a”
or “b”. Data are represented as mean ± S.E.M.
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Figure 22. qPCR analysis in whole heart tissue from mice treated with PYR for two
weeks following isoproterenol injections for 7 days.
qPCR quantification of a) vesicular acetylcholine transporter (VAChT), b)
acetylcholinesterase (AChE), c) high-affinity choline transporter (ChT1), d) adrenoceptor
β1 (Adrb1), and e) cholinergic receptor muscarinic 2 (Chrm2) in whole heart tissue.
mRNA was extracted using Aurum Fatty and Fibrous Tissue RNA Extraction Kit. cDNA
was then synthesized using the High Capacity cDNA Reverse Transcription Kit. qPCR
analysis was completed on ViiA 7 Real-Time PCR System using RT2 SYBER Green
ROX qPCR Mastermix. n = 10–13. Data are represented as mean ± S.E.M.
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were no measurable differences seen in gene expression in whole heart tissue. It has been
previously reported that treatment with ISO induces a change in gene expression in
cholinergic targets, such as VAChT and M2 (Gavioli et al., 2014). This suggests that
compensatory mechanisms in response to high sympathetic activity are increasing
cholinergic proteins. However, this was not seen in the present experiment. It is
suggested that the differences in protocol, duration of treatment, and time of sacrifice
contribute to the lack of changes seen in gene expression in whole heart tissue.
Expression of cardiac damage markers, Myh7 and ANP, is commonly increased
in response to heart failure. Myh7 is a cardiac structural gene that is involved in DNA
methylation. Myh7 expression was found to be unchanged with PYR treatment (1.0 ±
0.1079 and 1.099 ± 0.1497, n=10/treatment), Control and Control+PYR, respectively
(Figure 23). Treatment with ISO significantly increased in Myh7 expression when
compared to control mice (P = 0.0072, 1.0 ± 0.1079 and 1.459 ± 0.1064, n=10/treatment),
Control and ISO, respectfully. ISO+PYR treatment had no effect on Myh7 expression
when compared to ISO mice (Figure 23). Interestingly, ANP expression levels were not
changed in response to ISO. This may be due to the length of protocol and when tissue
was collected. ANP is a hormonal gene and its response to injury leads to dilation of
blood vessels, which was seen at the end of ISO injections (Figure 11). PYR treatment
caused no changes in expression levels of both Myh7 and ANP when compared with
control and ISO mice (Figure 23).
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Figure 23. Expression of cardiac stress markers in whole heart tissue from mice
treated with PYR for two weeks following isoproterenol injections for 7 days.
qPCR quantification of a) β-myosin heavy chain (Myh7) and b) atrial natriuretic peptide
(ANP) in whole heart tissue in mice treated with ISO for one week, followed by either
saline or PYR treatment following. mRNA was extracted using Aurum Fatty and Fibrous
Tissue RNA Extraction Kit. cDNA was then synthesized using the High Capacity cDNA
Reverse Transcription Kit. qPCR analysis was completed on ViiA 7 Real-Time PCR
System using RT2 SYBER Green ROX qPCR Mastermix. n = 10–12. Data are
represented as mean ± S.E.M.
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3.11 Hyper-sympathetic activity causes cardiomyocyte hypertrophy, cardiac fibrosis
and increased mortality.
Hearts from treated mice were subject to H&E staining to evaluate histological
changes and hypertrophic responses accompanied with ISO and PYR treatment. Figure
24a shows representative images of H&E stained heart sections. Cross sectional areas of
cardiomyocytes were found to be significantly higher in ISO treated hearts (Figure 24b).
Heart sections were also stained with Trichrome C to analyze the appearance of cardiac
fibrosis (Figure 24c). Both interstitial and perivascular fibrosis was seen in ISO treated
mice. Cardiac fibrosis was then quantified as a percent of total area (%) (Figure 24d).
This data suggests that PYR prevented the progression of fibrosis seen in ISO treatment.
A Kaplan-Meier curve is shown in Figure 25 to depict survival of treated mice
throughout protocol. There was a significant difference in survival percentages in mice
treated with ISO compared to other treatment groups, suggesting that hyper-sympathetic
activity is detrimental to health. As well, PYR was able to lessen the degree of mortality
seen in ISO treated mice (Figure 25).
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Figure 24. Isoproterenol-induced pathological changes to cardiomyocytes.
Hematoxylin and Eosin (H&E) staining of representative cross sections of heart tissue
from treated mice. a) Representative H&E stained cardiomyocyte sections. b)
Quantification of cross sectional area (μM2) of cardiomyocytes in treated mice. c)
Representative Trichrome C stained cardiomyocytes. d) Quantification of cardiac fibrosis
(% of total) of cardiomyocytes of treated mice. n = 9–12 for H&E stain and 3–7 for
Trichrome C stain. *P < 0.05. Data are represented as mean ± S.E.M.
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A Kaplan-Meier death curve. n = 10–14 / treatment. *P < 0.05.
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Chapter 4
4 DISCUSSION
Autonomic homeostasis is essential for proper cardiovascular function. Imbalance
of either sympathetic or parasympathetic control can lead to detrimental consequences for
cardiovascular health, as autonomic signaling regulates cardiac output, and cardiac output
determines the efficiency of the heart. Sympathetic overdrive, accompanied by the
decline in cholinergic signaling is most commonly seen in heart failure patients.
Targeting autonomic pathways for treatment of cardiovascular diseases has been noted by
many researchers. Most recently, cholinergic control has been highlighted for its potential
as an alternative target. Focusing on the diminishing parasympathetic activity seen in
heart failure, as oppose to blocking or preventing activity of sympathetic transmission for
treatment, has presented promising results. Our lab has previously shown that transgenic
mouse models, where cholinergic enzymes are knocked down, show poor cardiovascular
health, and have exaggerated cardiovascular damage in response to insults. However,
when these enzymes are overexpressed in cholinergic neurons, mice are better able to
withstand cardiac insults and show improved cardiovascular health. These
transgenic models show the importance of proper cholinergic function. Our objective was
to not only continue previous work done in our lab highlighting the importance of
cholinergic signaling in transgenic mice, but also move into a more clinically relevant
direction, where pharmacological therapies could also show this protection. I have
hypothesized that increasing cholinergic signaling will provide protection to better
maintain cardiovascular homeostasis in response to damage or insults. Using both ex vivo
and in vivo experiments and models, I have found that restoring or increasing cholinergic
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transmission in response to cardiovascular insults is protective and suggests an alternative
target for future treatment regimes.

4.1 Isoproterenol can be used as a model of cardiomyopathy.
Noted previously, autonomic dysregulation is commonly seen in heart failure
models. In response to a failing heart, the sympathetic system is activated to maintain
proper cardiac output and perfusion to peripheral organs. What starts out as a
compensatory mechanism, can often lead to chronic adrenergic stimulation, and this
constant exposure to catecholamine release can be detrimental. Constant stimulation of βAR can lead to cardiac stress, increasing levels of inflammatory markers in circulation,
further contributing to the pathology of heart dysfunction. Cardiac hypertrophy, seen as a
precursor to heart failure, is often a compensatory mechanism to maintain cardiac output
in response to increased myocardial demand (Madamanchi, 2007). As the heart continues
to respond to increasing stress, ventricular function eventually declines, continuously
activating sympathetic activity to compensate, further increasing the workload of the
heart. A sustained increase in cardiac hypertrophy in response to an increase in workload
can lead to ventricular dilation and heart failure (Sukoyan et al., 2017). Previous research
investigating the effects of hyper-activity of sympathetic signaling showed an increase in
both anterior and posterior ventricular wall thickness, without a substantial change in
internal diameter in mice treated continuously with ISO for both three and 14 days (Puhl
et al., 2016). Presently, I found that after only seven days of intraperitoneal bolus
injections with ISO, ventricular anterior and posterior walls were significantly thicker
compared to control hearts, and this was also accompanied with no change in internal
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diameter. This observation, known as concentric hypertrophy, occurs in response to
increases in workload and oxygen demand (Mihl et al., 2008). Prolonged concentric
hypertrophy causes increases in force and pressure, and can cause impairments of
ventricular filling leading to diastolic dysfunction (Mihl et al., 2008). Previously, ISO
treatment was shown to cause left ventricular hypertrophy that was unrelated to blood
pressure or increased end diastolic pressure, as blood pressure was decreased due to
activation of β2 receptors in the vasculature (Ocaranza et al., 2002). Our data show that
after ISO treatment, hearts exhibited hypertrophy, accompanied with a decrease in
systolic and diastolic blood pressure.
Previous studies have shown increases in heart weight and lung weight in
response to ISO treatment (Ocaranza et al., 2002; Roy et al., 2012; Puhl et al., 2016). The
present study showed an increase in heart weight to body weight ratio in ISO treated mice
compared to control, indicative of hypertrophy. However, lung weight was unchanged,
most likely a result of differences in experimental timelines, as tissues were not harvested
until two weeks after the cessation of ISO injections. The current study first treated mice
with ISO for seven consecutive days after which mice were then treated for two weeks
with saline and or an AChE inhibitor. Only after the two-week treatment were mice
sacrificed and their tissues harvested. The dose of drug used may also contribute to the
pathological changes seen in the present study. Compared to previous studies utilizing
ISO, a higher concentration was used in the present experiment, and this may have
induced maladaptive responses seen not only as hypertrophy, but cardiac remodeling and
fibrosis as well. It is suggested that the previous study used a model of compensatory
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hypertrophy as cardiac function was increased but no suggestion of fibrosis (Puhl et al.,
2016).
To confirm echocardiographic assessment of hypertrophy, histology was
performed in ventricular tissue of mice and cross sectional area (CSA) of cardiomyocytes
was measured. It was shown that mice treated with ISO have increased CSA of
cardiomyocytes, reaffirming previous data (Rocha-Resende et al., 2012; Puhl et al.,
2016). Histological staining of cardiomyocytes with Trichrome C also illustrated that
both perivascular and interstitial fibrotic tissue accumulated in mice treated with ISO.
Previous experiments have shown isoproterenol perfusion increases CSA and collagen
disposition in mice (Oudit et al., 2003). This group also noted that cardiac function was
decreased, indicated by decreased fractional shortening, decreased blood pressure, and
beta receptor downregulation (Oudit et al., 2003). In the present study, although blood
pressure, both systolic and diastolic, was decreased post ISO injections, there was no
detectable change in the expression of β1 adrenergic receptor. This may be due to
differences in the mode of administration, continuous or bolus injections, and the time of
tissue harvest. Future studies may include use of selective β-AR or antagonists to assess
the degree of desensitization or downregulation in response to ISO injections.
Mentioned earlier, increased levels of circulating inflammatory cytokines are
often correlated with declining heart function (Pavlov & Tracey, 2005; Shirazi et al.,
2017). Cardiac hypertrophy occurs due to an imbalance of pro- and anti- inflammatory
markers. This increase in pro-inflammatory marker levels is often a response to a
mechanically stressed heart. In the current study, ISO injections caused an increase in
mechanical stress. Increasing stress on the heart can induce a state of compensatory
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hypertrophy, further increasing activation for sympathetic activity, in combination with
increases in cytokine expression (Yndestad et al., 2006). The present study indicated that
treatment with ISO caused an increase in both TNF-alpha and IL-6 cytokine levels in
plasma following the seven-day treatment. These cytokines are most commonly
associated with myocardial failure, as they can induce dysfunction, hypertrophy,
apoptosis and fibrosis (Yndestad et al., 2006). While increases in TNF-alpha are known
to cause cardiomyocyte dysfunction, hypertrophy, fibrosis and ventricular dilation,
increases in IL-6 show hypertrophy and fibrosis but results in diastolic dysfunction
(Shirazi et al., 2017). Whether these mediators are released from the myocardium itself or
from some other source, their expression is suggested to contribute to the model of ISO
induced hypertrophy and fibrosis.
Atrial natriuretic peptide (ANP) and beta-myosin heavy chain (Myh7) expression
have been previously used as an indicator of cardiac damage (Sergeeva & Christoffels,
2013; Wang et al., 2014). Myh7 is a cardiac structural gene, whereas ANP is a hormonal
gene that is expressed in response to injury and its protection includes dilation of blood
vessels (Morita et al., 2005; Wang et al., 2014). In response to aging or pressure overload
models, researchers show an increase in Myh7 in heart tissue (Nakao et al., 1997). In the
present study, a significant increase in Myh7 expression was seen in heart tissue from
ISO mice compared to Control. While Myh7 has also been noted as a cardiac marker of
hypertrophy (Ruggiero et al., 2013), ANP is known as a marker of chronic congestive
heart failure and is released in response to atrial stress (Brandt et al., 1993; Goetze et al.,
2015). As well, insufficient ANP can lead to cardiac hypertrophy, fibrosis, dilation and
heart dysfunction (Wang et al., 2014). This may suggest that ISO treatment in the present
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study cannot be utilized as a true model of congestive heart failure, but rather
hypertrophic cardiomyopathy.
Although well researched, the mechanisms underlying the higher sympathetic
activity found in patients with heart failure are not completely understood. Researchers
interested in this topic have proposed several possible explanations, from downstream
signaling molecules and their effect on ion channels to mitochondria dysfunction. Upon
activation of β1-AR at the heart, the coupling with Gs protein causes an increase in cAMP
levels due to activation of adenylate cyclase. cAMP is responsible for increases in the
force of contraction, decreasing duration between systole and diastole, and can mediate
Ca2+ dependent proteins. As with any physiological process, constant exposure to
sympathetic transmission can become detrimental to cardiac homeostasis, as increased
catecholamine levels can cause increases in mechanical load and overcompensation.
Consistently higher levels of cAMP can cause downregulation of β1 -AR, and
simultaneously increase Gi protein expression, to attenuate further cAMP synthesis
(Eschenhagen et al., 1992; Nikolaev et al., 2016). β2-AR can become the dominant
adrenergic beta receptor in the failing heart; and if stimulated constantly, can induce
CaMKII-dependent responses contributing to cardiomyocyte hypertrophy, remodeling,
and dysfunction by Ca2+ overload (Anderson et al., 2011; Boularan & Gales, 2015).
It has been noted that in response to increases in cAMP and Ca2+ overload, there
are high-energy phosphate deficiencies caused from excessive activation of calcium
dependent ATPases. This may also be due to Ca2+ induced dysfunction of the
mitochondria. This dysfunction has been noted to cause an increase in oxygen derived
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free radicals, which can further cause oxidative stress and cardiac damage (Mann et al.,
1992; Brown et al., 2017).
In addition, relative hypoxia is a model where the myocardial oxygen demand
exceeds current blood flow and is caused by the increase in cardiac inotropic and
chronotropic properties of adrenergic stimulation. Previous studies have also shown that
treatment with ISO can cause a decrease in coronary blood flow, inducing this hypoxic
state due to increased levels of circulating catecholamines (Mann et al., 1992). The
hypoxic state will eventually cause cell apoptosis and heart dysfunction or failure
(Giordano, 2005). Moreover, the imbalance between oxygen supply and demand
following coronary and systemic hypotension, in addition to the increase in heart activity
due to catecholamine levels, contributes to the relative hypoxic model and can cause
further tissue damage if sustained (Grimm et al., 1998).

4.2 Increasing cholinergic activity can protect the heart against injury.
As noted earlier, an increase in sympathetic activity is commonly associated with
a decrease in parasympathetic signaling in heart failure. Previous work in our lab has
focused on transgenic models of hyper-cholinergic genotypes and their ability to better
maintain cardiovascular function in response to stressors or insults. Mouse models, where
ChAT or VAChT are genetically knocked out in cardiomyocytes, show increased HRV
and altered regulation when exercising (Roy et al., 2016) . As well, these mice show
cardiac dysfunction through hypertrophic responses and cardiac remodeling (Roy et al.,
2016). Acetylcholinesterase inhibition has also been shown to improve and increase heart
rate recovery in patients with chronic heart failure (Androne et al., 2003).
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In the present study, ex vivo models show that mice overexpressing VAChT in
cholinergic cells are protected against ischemic reperfusion injury; characterized by
maintained cardiac function and decreased necrotic tissue damage post injury.
Interestingly, when wild type hearts were treated with the AChE inhibitor PYR, the
ability to maintain heart function and prevent necrosis following ischemic injury was
apparent. These experiments suggest a protective characteristic of increased cholinergic
signaling and available ACh in response to stress. Although the mechanism is unknown,
there are several proposed explanations to explain why increasing ACh is protective in
response to cardiac insults.
During an ischemic reperfusion injury, cardiac tissue is deprived of oxygen and
nutrients, leading to decreased oxygen supply to the heart and can cause tissue injury.
Increasing available ACh, either through transgenic models or pharmacological
treatment, may improve perfusion to the heart by decreasing heart rate and increasing
coronary dilation and diastolic period, ultimately decreasing oxygen consumption (Lataro
et al., 2013). As well, available ACh will decrease cardiac afterload, relieving the heart of
mechanical load, preventing the prevalence of damage or remodeling (Lataro et al.,
2015).
In the current study, treatment in vivo with PYR was able to increase systolic and
diastolic blood pressure following ISO injections, re-establishing or further preventing
systemic hypotension. As well, PYR was shown to decrease myocardial activity, seen
through significantly lower ejection fraction and decreased heart rate, preventing further
mechanical stress on the heart. Attenuating the decrease in blood pressure and the
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increase in heart activity restores proper oxygen supply and demand and perhaps provides
protection against further tissue damage.
In addition, PYR was able to prevent or reduce severity of cardiac hypertrophy
and fibrosis seen in cardiomyocytes of mice treated with ISO in vivo. β-AR cause a
tachycardic response increasing myocardial demand, ultimately increasing oxygen
demand. This in turn can cause a decrease in coronary artery perfusion and a decline in
oxygen available to the heart. Relative hypoxia occurs when myocardial oxygen demand
exceeds current blood flow. This phenomenon has been reported in ISO treated models
(Mann et al., 1992). Treatment with acetylcholinesterase inhibitors increase available
ACh and has potential to increase perfusion through coronary arteries and relive the heart
of stress, preventing hypertrophy and fibrosis or ventricular stiffening to occur in
cardiomyocytes (Wang et al., 2014). More clinically applicable, patients suffering with
coronary artery disease show protection against myocardial ischemia through treatment
with PYR (Nobrega et al., 2008). In the present study, available ACh following
sympathetic over-drive treatment prevented or reversed cardiac hypertrophy and fibrosis.
Perivascular fibrosis seen in cardiomyocytes from mice treated with ISO can cause
remodeling and narrowing in coronary arties, contributing to the relative hypoxic state
due to decreased coronary blood flow (Wang et al., 2014). It is suggested that increased
cholinergic signaling can re-establish coronary blood flow by relieving perivascular
fibrosis.
It is also worth noting that treatment with ISO significantly increased mortality in
mice, shown in Figure 3.23. Treatment with PYR was able to increase survival of mice
treated with ISO. This data suggests that constant hyper-activity of sympathetic
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transmission is detrimental to survival and increasing cholinergic signaling can improve
this. Clinical trials with patients suffering from Alzheimer’s show that treatment with
donepezil, a centrally acting AChE inhibitor, decreases cardiovascular mortalities seen in
patients (Sato et al., 2010). It was recently suggested that restoring autonomic balance by
increasing cholinergic signaling can be beneficial for elderly as parasympathetic
signaling declines with age. The present data suggests that perhaps increasing cholinergic
signaling in patients suffering from cardiovascular disease will also decrease mortality.
The cholinergic system is well-known for its anti-inflammatory properties. ACh
binds to the alpha 7 subunit of the nicotinic cholinergic receptor on macrophages to
inhibit the release of cytokines (Rosas-Ballina & Tracey, 2009; Lataro et al., 2015). Proinflammatory cytokines can lead to the progression of inflammation, hypertrophy and
remodeling (Pavlov et al., 2003). Preventing the release of cytokines into circulation,
through the inhibition of AChE, can possibly prevent cardiomyocyte inflammation and
hypertrophic responses seen in heart failure. However, it was previously noted that these
anti-inflammatory effects produced by AChE inhibitors were dependent on central
cholinergic pathways (Lataro et al., 2015). The present study utilized PYR, a peripheral
reversible acetylcholinesterase inhibitor, which is unable to cross the blood brain barrier
(BBB). When comparing treatments of PYR and donepezil (DON) in a model of
spontaneously hypertensive rats, there was an absence of anti-inflammatory effects with
the use of PYR but these effects were apparent in DON treated models (Lataro et al.,
2015). DON, most commonly used for the treatment of Alzheimer’s, is a centrally acting
AChE inhibitor and can cross the BBB. In the present study, although there was an
increase in pro-inflammatory markers in response to ISO treatment, cytokines levels were
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unchanged in response to PYR treatment. This observation may be a result of the specific
cholinesterase inhibitor used.

4.3 Conclusion.
I have demonstrated that in response to cardiac insults, the cholinergic system is
able to show protection against tissue damage, injury and aids in the maintenance of
cardiovascular homeostasis. Ex vivo experiments have shown the importance of nonneuronal ACh, as hearts from hyper-VAChT mice show protection against ischemic
reperfusion injury and can better maintain function. Moreover, with use of
pharmacological intervention, acetylcholinesterase inhibitors were also shown to protect
hearts against injury. Non-neuronal ACh is protective in response to stressors or injury
through ex vivo analysis. When mice were treated in vivo with PYR, there was no
noticeable differences in cardiovascular parameters, suggesting that during baseline
conditions, increasing available ACh is inconsequential to both hemodynamic properties
and heart function. However, when mice were treated with ISO, a non-selective beta
adrenergic agonist, causing a state of sympathetic hyperactivity, PYR was able to protect
mice from further cardiovascular deterioration, noted by decreasing hypertrophic
responses of cardiomyocytes through histological and echocardiogram analysis and
visibly decreasing prevalence of collagen deposition. Although there are many possible
explanations to the specific mechanism of how ACh exerts protection on cardiovascular
health, it is most likely a combination effect. Specifically, the anti-inflammatory effects
of cholinergic signaling, re-establishment autonomic homeostasis, prevention of
myocardial relative hypoxia, and maintenance of proper Ca2+ intracellular concentrations
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and mitochondria function all contribute to the protection seen in models of increased
cholinergic transmission in response to insults. Overall, this data suggests potential
therapeutic treatments by targeting cholinergic transmission to restore autonomic balance
in cardiovascular disease.

4.4 Limitations and Future Directions.
Our data shows that after one week of sympathetic overdrive, treatment with
PYR, an acetylcholinesterase inhibitor, can not only prevent the progression of
cardiovascular damage, but suggest that pathological responses can be reversed by
increasing available ACh. Extending the duration of ISO treatment, mimicking a chronic
hyper-sympathetic model, may suggest or provide further knowledge regarding
cardiovascular responses like those seen in heart failure models.
ISO was used in this experiment as it provides direct activation of β-AR
contributing to a hypertrophic and mild heart failure phenotype. However, angiotensin II
(AngII) has previously been used and has been highlighted for its effect, specifically
regarding renal and cardiovascular function. AngII is responsible for vasoconstriction,
salt and water retention, inflammation, and cell death (Zablocki & Sadoshima, 2013).
Imbalances in renin-angiotensin system (RAS) can cause hypertension and cardiovascular
dysfunction (Crowley et al., 2006). The response to AngII leads to increases in reactive
oxygen species, which can cause oxidative stress and tissue injury (Zablocki &
Sadoshima, 2013). AngII acts on AT1 receptors in many organs, including the heart,
vasculature and kidneys to cause hypertension (Crowley et al., 2006). It would be of great
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interest to investigate the effect of cholinergic-boosting treatments in response to AngII,
as the mechanism contributing to cardiovascular damage differs from ISO.
In addition, the intervention duration and timeline can also be evaluated for future
experiments. Although the current study investigated PYR treatment after catecholamine
cardiotoxicity, perhaps treatment with PYR before or during the insult may provide more
insight as to how ACh availability can attenuate myocardial hypertrophy and at what
stage of cardiotoxicity is most vulnerable to damage. Also, although not performed in
present experiments, evaluating hyper-sympathetic and cholinergic treatment and its
effect on peripheral organs other than the heart, would provide a broader understanding
of peripheral actions of autonomic treatment on both extremes.
Treatment with ISO as a model of hypertrophy and heart failure can be noted as a
limitation of our model. It is important to note that I was interested in investigating the
effect of PYR in response to cardiovascular damage. It is well known that in heart failure,
patients are commonly seen with increases in sympathetic activity, accompanied by
decreases in parasympathetic signaling. Perhaps using a more concrete model of heart
failure, such as coronary artery ligation induced myocardial infarction or a transgenic
model, would provide more insight as to how enhanced cholinergic signaling can protect
the heart against damage. However, focusing on pharmacological treatment, and straying
away from transgenic models highlights the clinical potential.
Although the present study provides evidence to suggest that hyper-sympathetic
activity is detrimental to cardiac function, providing further analysis into specific neurohormones and cytokines may provide more evidence, as heart failure has been noted as a
progressive model. Brain natriuretic peptide (BNP) is known as a marker for heart failure
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and is released by ventricle tissue. Quantification of BNP expression may further indicate
the hypertrophic state of hearts treated with ISO.
It is well known that mitochondrial dysfunction can cause cardiac hypertrophy,
and re-establishing proper autonomic control through cholinergic signaling has the
potential to reverse the heart failure phenotype. Specifically, analyzing the levels of
oxidative stress markers in circulation or at the level of cardiomyocyte may further
indicate whether the mitochondria plays a crucial role in the development of cardiac
dysfunction and/or the protection seen from ACh.
As well, the present study investigated expression of pro-inflammatory markers in
the plasma. However, it would be more reliable to quantify these levels in cardiac tissue
or the spleen. Targeting the source of inflammatory markers would enable for a greater
understanding of the role of inflammatory markers in response to cardiac damage.
Investigating changes of anti-inflammatory levels in treated mice, as oppose to proinflammatory markers, would also be of interest. I have shown that pro-inflammatory
markers, TNF-alpha and IL-6, were increased in plasma of ISO treated mice. However, it
is unknown how ISO or PYR treatment affects the expression of anti-inflammatory
markers. This may contribute to the understanding of how ACh exerts its protection on
cardiac health.
Furthermore, limitations to my study also include the varying sample sizes both
within experiments and amongst experiments. To correctly and objectively compare
treatment groups, it is advantageous to keep the sample size consistent to avoid unreliable
comparisons. Although the findings are limited to the model we used, highlighting an
important pathophysiological feature of heart disease, sympathetic overdrive, allowed us
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to investigate how increases in catecholamine release are detrimental to cardiac function
and that increasing cholinergic signaling through inhibition of acetylcholinesterase can
prevent or improve damage.
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